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Introduction
1. INTRODUCTION
Tuberculosis  is  a  disease  of  great  antiquity.  There  is  evidence  of  spinal  tuberculosis  in 
Neolithic, pre Columbian and early Egyptian remains. It was described in the Vedas and other Hindu 
texts as Rajyakshma-the king of diseases. Tuberculosis became a major problem during the industrial 
revolution, when crowded living conditions favoured its spread. Though the disease was known since 
ancient times, the organism causing tuberculosis was described only a century ago by Robert Koch on 
24th March 1882.
1.1 The agent
The  term  tubercle  bacillus  designates  two  species  of  the  family  Mycobacteriaceae,  order 
Actinomycetales:  M.  tuberculosis  and  M.  bovis.  Three  other  species  –  Mycobacterium  microti,  a 
pathogen  for  rodents,  Mycobacterium  africanum and  Mycobacterium  canetti,  both  rare  causes  of 
tuberculosis in Africa are closely related and are the other members of the M. tuberculosis complex. 
The complex also contains BCG vaccine, derived from a strain of M.bovis. Disease caused by M. bovis 
is relatively rare, and the terms tubercle bacillus and Mycobacterium tuberculosis are synonymous.
1.2 The genome
Evenly distributed genes along both the strands of DNA of M.tuberculosis and  single copy of 
the ribosomal RNA operon located at unusually 1500 kb from the origin of replication explains the 
slow growth  and  its  24  hr  generation  time.  Presence  of  genes  encoding  aerobic  metabolism  and 
anaerobic electron transport chain enable the bacilli to survive in granulomas or oxygen poor tissues. 
The  high  genetic  variability  of  PE and PPE families  of  glycerin  rich  proteins  interfere  with  host 
immune responses by inhibiting antigen processing. The richness of insertion sequences (IS) may be 
the source of chromosomal rearrangements and deletions (Topley and Wilsons p.1186).  
1.3 The Pathogenesis  
Airborne  droplet  nuclei  containing  tubercle  bacilli  reach  the  terminal  air  spaces  where 
multiplication  begins.  The  bacteria  are  ingested  by  alveolar  macrophages,  which  may  be  able  to 
eliminate  small  numbers  of  bacilli.   Protective  immunity  is  mainly  cell  mediated.  However,  the 
bacterial  multiplication tends to  be mostly unimpeded and can survive inside the macrophages  by 
preventing the oxidative burst and phagosome lysosome fusion. The bacilli resist lysosomal enzymes 
and ROI by virtue of cell wall lipids. Multiplication of bacilli leads to cell death and local inflammation 
which attract more phagocytes to the site. Some are transported to the regional lymph nodes and others 
further afield causing extra pulmonary tuberculosis.
Epitopes from mycobacteria are presented by the APCs to CD4+ cells,  which on activation 
produce a range of cytokines including IFN-γ that activate the macrophages to form the granulomas 
and  multinucleated  giant  cells.  Cytotoxic  CD8+  T  cells  are  also  generated  to  lyse  the  infected 
mononuclear  phagocytes  directly.  The  center  of  granuloma is  anoxic  and caseous  necrosis  occurs 
which kills many bacilli. TNF-α plays a key role in protective immunity by maintaining the integrity of 
the granuloma. In about 95% of the primarily infected patients these defense mechanisms render the 
disease quiescent, but some may survive for years or decades in a latent state to be reactivated later 
(Topley and Wilsons p.1202).   
1.4 Revised National Tuberculosis Control Programme Guidelines
RNTCP is  an application in India of the WHO recommended Directly Observed Treatment 
Short Course (DOTS) strategy to control Tuberculosis. Tuberculosis cases are classified as pulmonary 
and extra-pulmonary. 
1.4.1 Pulmonary tuberculosis
Pulmonary Tuberculosis is further classified as smear positive and smear negative.
a. Smear-positive patient
- 2 sputum positive for acid-fast bacilli (AFB). 
- 1 sputum positive for AFB + Radiographic abnormalities.
- 1 sputum positive for AFB + Culture positive for M.tuberculosis.
b. Smear-negative patient
- 3 sputum negative for AFB but with Radiographic abnormalities.  
- 3 sputum negative for AFB but Culture positive for M. tuberculosis.
Seriously ill smear-negative Pulmonary TB cases are
-Miliary Tuberculosis, Extensive parenchymal infiltration, Co-infection with HIV, all forms of 
pediatric sputum smear negative pulmonary tuberculosis except primary complex.
1.4.2 Extra Pulmonary Tuberculosis (EPTB)
This includes Tuberculosis of organs other than the lungs. Patients with both pulmonary and 
extra-pulmonary are classified as having Pulmonary Tuberculosis. 
Seriously ill EPTB cases are described in table 1.1.
Any  patient,  with  Pulmonary  or  Extra  Pulmonary  Tuberculosis,  who  is  HIV  positive, is 
considered as seriously ill.
1.4.3 Case definitions 
Tuberculosis patients are designated as
New - never had treatment for Tuberculosis or had treatment for less than a month.
Relapse - declared cured or treatment completed, but found to be sputum positive later.
Treatment after default  - had ATT for one month or more and returns to treatment after not taking 
drugs consecutively for two months or more, and is sputum positive.
Failure -  smear positive after 5 months of treatment and Category III patients who becomes smear 
positive during treatment.
Chronic - remains smear positive after completing re-treatment regimen.
The categories of treatment and the schedule for follow-up sputum examinations during entire course 
of treatment under RNTCP are described in table 1.2 and 1.3 respectively.
1.5 Drug resistance
As the programme strives hard to achieve its goals, it is at present facing the threat of drug 
resistance, a menace that would destabilize the tuberculosis control. 
Drug resistance as a limiting factor for success of chemotherapy was recognized immediately 
following the introduction of Streptomycin. Youmans et al 1946 found that when Streptomycin was 
given alone, there was a rapid decrease in the number of bacilli in the sputum which however increased 
again. Pyle (1947) showed that during treatment with Streptomycin alone, the proportion of drug-
resistant bacilli increased progressively from about 1 in 88,750 organisms before therapy, to about 1 in 
367 after 15 weeks of treatment. Studies by Crofton and Mitchison (1948) showed that with 
monotherapy or inadequate therapy, the number of susceptible bacilli Table 
1.1 Extra Pulmonary Tuberculosis (EPTB)
Seriously ill EPTB Not seriously ill EPTB
• Meningitis
• Pericarditis
• Peritonitis
• Bilateral or extensive pleural effusion
• Spinal TB with neurological involvement
• Intestinal
• Genito-urinary
• Co-infection with HIV
• All forms of pediatric Extra pulmonary
tuberculosis other than lymph node 
tuberculosis
and unilateral pleural effusion.
• Lymph node
• Pleural effusion (unilateral)
• Peripheral joints
Table 1.2 Categories of Treatment
Category of
Treatment
Type of Patient
                        Regimen*
Intensive        
phase
Continuation 
phase
Category I New sputum smear-positive
Seriously ill new sputum smear-negative
Seriously ill new extra-pulmonary
2H3R3Z3E3 4H3R3
Category II Sputum smear-positive Relapse
Sputum smear-positive Failure
Sputum smear-positive Treatment After
Default
2H3R3Z3E3S3
+ 1H3R3Z3E3 
5H3R3E3
Category III New Sputum smear-negative, not seriously ill
New Extra-pulmonary, not seriously ill 2H3R3Z3 4H3R3
*The number before the letters refers to the number of months of treatment. The subscript after the letters refers 
to the number of doses per week. The dosage strengths are as follows: H: Isoniazid (600 mg), R: Rifampicin 
(450 mg), Z: Pyrazinamide (1500 mg), E: Ethambutol (1200 mg), S: Streptomycin (750 mg).
Table 1.3 Schedule for follow-up sputum examinations during entire Course of treatment
  Category  Pretreatment
 sputum
 Test
    at
mont
h
If
result
is
Then…
Category  I
Positive   2
NEG Start continuation phase, test sputum again at 4 and 6 months
POS
Continue intensive phase for one more month, test sputum 
again at 3, 5 and 7 months
 Negative   2
NEG Start continuation phase, test sputum again at 6 months
POS
Continue intensive phase for one more month, test sputum 
again at 3,5 and 7 months
Category II  Positive   2
NEG Start continuation phase, test sputum again at 5 and 8 months
POS
Continue intensive phase for one more month, test sputum 
again at 4,6 and 9 months
Category III  Negative   2
NEG Start continuation phase, test sputum again at 6 months
POS Re-register the patient and begin Category II treatment
(RNTCP Training Module, 2006)
decreased, while the resistant bacilli increased in lung cavities of the patients. This was called the ‘‘fall 
and rise” phenomenon.
Temple and associates (1951) showed that multiple drug therapy would prevent development of 
drug resistance and tuberculosis patients were then treated only with multiple drugs. 
There are several antimicrobial drugs currently being used for the treatment of Tuberculosis. 
These include first line drugs such as Isoniazid, Rifampicin, Streptomycin, Pyrazinamide and second 
line  drugs  like  Aminoglycosides  (Amikacin,  Kanamycin),  Quinolones,  Para  Amino  Salicylic  acid, 
Cycloserine, Thioamides (Ethionamide, Prothionamide), Polypeptides (Capreomycin). 
1.5.1 WHO Definitions of Drug Resistance
Drug resistance among new cases:
-  the  presence of  resistant  isolates  of  M.tuberculosis  in  patients  who,  in  response to  direct 
questioning, deny having had any prior anti-TB treatment (for as much as 1 month). 
Drug resistance among previously treated cases:
-  the  presence of  resistant  isolates  of  M.tuberculosis  in  patients  who,  in  response to  direct 
questioning, admit having been treated for tuberculosis for 1 month or more  (Anti-tuberculosis drug 
resistance in the world, WHO Fourth Global Report 2008). 
Multi-Drug Resistant Tuberculosis (MDR-TB): 
Resistance to Isoniazid and Rifampicin with or without resistance to other first line drugs.
Extensively Drug-Resistant Tuberculosis (XDR TB): 
MDR-TB with added resistance to at least two (Flouroquinolones & Injectable agent) of the six main 
classes of second line drugs.
1.5.2 Mechanism of Resistance in Mycobacterium Tuberculosis
Genetic mutation:
 Resistance in  M.tuberculosis  is always a result of mutations confined to chromosomal DNA.
The  MDR phenotype  is  caused  by accumulation  of  mutations  involved  in  individual  drug 
resistance.  The probability of resistance is
Very high: - Thiacetazone, Ethionamide, Capreomycin and Cycloserine (10-3); Intermediate:  - 
INH, SM, EMB, Kanamycin, and PAS (10-6); 
Lowest: - Rifampicin (10-8).  Shimao 1987; Crofton 1970).
The  mutation  rate  is  directly  proportional  to  the  bacterial  load.  These  mutations  being 
chromosomal, simultaneous resistance to two or more drugs is extremely unlikely. Serial selection of 
drug resistance is the predominant mechanism for the development of MDR strains.
Mutants resistant to one drug are, as a rule, susceptible to other and vice versa. Only mutants 
resistant to both drugs simultaneously are a cause of concern when the concentration is exceptionally 
low  (Canetti  1961), which is  rare.  When bacterial  population diminishes,  there is  little  chance for 
mutants resistant to one drug and no likelihood of presence of multi resistant mutants. The various 
Gene Loci conferring drug resistance to MTB is listed in Table -1.4.
Table 1.4 Various Gene Loci conferring drug resistance to MTB
Drug Gene Gene product/functional role Cellular target
RIF rpoB β-subunit of RNA polymerase/transcription Nucleic acids
INH katG
inhA
oxyR-ahpC
Catalase-peroxidase/activation of Pro-drug
enoyl-acyl carrier protein reductase / mycolic acid 
biosynthesis
Alkyl-hydro-reductase/unknown
Cell Wall
kasA b-ketoacyl acyl carrier protein/ mycolic acid biosynthesis
SM rspl
rrs
Ribosomal protein S12/translation
16S rRNA/translation
Protein 
synthesis
FQ gyrA DNA gyrase subunit / DNA replication Nucleic acid
PZA pncA pyrazinamidase-nicotinamidase / activation of prodrug Unknown
EMB embB Arabinosyl transferase/arabinan polymerization Cell Wall
Role of multidrug transporters:
Low-level drug resistance is due to multidrug efflux systems of bacterial cells which limit the 
access of antimicrobial agents to their targets.
P-glycoprotein is a human analogue of these multidrug transporters and is expressed on immune 
effector cells (Verbon et al 2002). It has been observed that infection of experimental cell lines by M. 
tuberculosis results in increased expression of P-glycoprotein and decreased accumulation of Isoniazid 
inside  the  cells  (Gollapudi  et  al  1994). Apart  from the  up  regulation  of  host  cell  P-glycoprotein, 
M.tuberculosis per se expresses at least three multidrug transporter proteins Tap, Lfr A and Mmr (De 
Rossi et al 1999). 
1.5.3 Significance of MDR-TB
Isoniazid and Rifampicin, the two most potent antituberculous drugs, kill more than 99% of 
tubercle  bacilli  within  2 months  of  initiation  of  therapy  (Iseman and Madsen,  1989). Isoniazid  is 
critical early in therapy; its bactericidal activity rapidly reduces the sputum viable count because it is 
active mainly against the organisms growing aerobically in pulmonary cavities  (Drake 1999; Hobby 
1952).
 Rifampicin is important in killing organisms that are metabolizing slowly, killing the persisters 
and sterilizing the patient’s sputum (Grumbach et al 1970). 
Along with these two drugs, Pyrazinamide, with a high sterilizing effect, appears to act on semi 
dormant bacilli not affected by any other antituberculous drugs. It is only active at low pH; making it 
ideally  suitable  for  killing  the  organisms  inside  caseous  necrotic  foci  explaining  the  finding  that 
Pyrazinamide  appears  to  have  no  benefit  after  the  second month  of  therapy  (East  African/British 
Medical Research Councils, 1981). 
Therefore, the emergence of strains resistant to these drugs causes major concern, as it leaves 
only drugs that are far less effective, have more toxic side effects, and result in higher death rates, 
especially among HIV-infected persons.
The HIV epidemic has completely destabilized the Tuberculosis control in high HIV prevalent 
regions.  An  estimated  one  third  of  the  persons  living  with  HIV  infection  are  co  infected  with 
tuberculosis.  HIV infection and MDR-TB was a perfect storm together and in 1993, WHO took an 
unprecedented step and declared Tuberculosis to be a global emergency. 
Diabetic patients are more susceptible to have an aggressive course of tuberculosis. With regard 
to the possible effects of DM on the outcome of TB, recent data are scarce. However studies show that 
they pose higher risk for spread of drug-resistant mycobacteria in the community. These issues require 
urgent attention.
Infections  due  to  Non tuberculous  mycobacteria are  on  the  rise.  They were  not  deemed 
significant pathogens until the mid 20th century with the emergence of pulmonary infections in patients 
with  pre-existing  lung  diseases.  Subsequently  the  AIDS  epidemic  has  also  brought  forth  drastic 
increase in NTM infections.
Human error is the principal factor associated with the emergence of drug resistant strains of 
M.tuberculosis. Prescription  of  inadequate  chemotherapy,  receiving  improper  treatment  outside  the 
National Programme from private qualified, or even unqualified practitioners, use of drugs of unproven 
bioavailability, patient’s lack of knowledge of the treatment, difficulty experienced by poor patients 
due to lack of financial resources, shortages of drugs due to poor management and financial constraints 
in developing countries, poor case-management when the treatment is not directly observed are some 
of the reasons for the rise of multidrug resistance. 
Today,  with  the  greatly  expanded  efforts  to  strengthen  tuberculosis  prevention  and control 
programmes worldwide, there is growing concern about the currently reported and potential future rates 
of drug-resistant tuberculosis. The resistant cases must be identified as swiftly as possible when they 
present at health care facilities so that they do not pose a threat to the community. To assess the extent 
of drug-resistant  M.tuberculosis strains harbored among re-treatment pulmonary tuberculosis patients 
and analyse the factors  that  had contributed to  it,  the present  study was undertaken at  Tirunelveli 
Medical College. 
Aim and Objectives
AIM AND OBJECTIVES
 To analyse the risk factors that had led to retreatment of the study group
 To study the profile of drug sensitivity pattern of CAT II patients and correlate it with the socio 
demographic status of these patients
 To assess the influence of risk factors like socio demographic characteristics, DM, HIV status, 
smoking and previous treatment as a marker for the development of Drug Resistant TB in the 
study group. 
Review of literature
3. REVIEW OF LITERATURE
“I have no business to live this life if I cannot eradicate this horrible scourge from the 
mankind,”-Robert  Koch, delivering a lecture at  Berlin University on his discovery of tuberculosis 
bacilli, 1882.
It has been 125 years since Robert Koch first discovered the tuberculous bacilli and the world is still 
fighting hard to control the disease. The poor and developing countries are still  in the grip of TB. 
Almost 40 years after introduction of combination chemotherapy for TB, and with the accumulated 
knowledge  of  the  mechanisms  leading  to  development  of  drug  resistance,  drug  resistant  TB, 
particularly MDR forms, remain a barrier to TB control.
3.1 The Global Burden of Tuberculosis             
There  were  an  estimated  9.2  million  new  cases  of  Tuberculosis  in  2006  (139/  1,00,000 
population) including 4.1 million new smear-positive cases (44% of the total). India, China, Indonesia, 
South Africa  and Nigeria  rank first  to  fifth  in  terms of  absolute  numbers  of  cases.  There was an 
estimated 4, 90,000 cases of multidrug-resistant Tuberculosis (MDR-TB) causing more than 1, 30,000 
deaths. 1.7 million people died of Tuberculosis in 2006 including 2,31,000 people with HIV. This is 
equal to 4,500 deaths a day. By March 2008, XDR-TB cases had been confirmed in more than 45 
countries and in all regions of the world. WHO estimates around 40,000 XDR-TB cases emerge every 
year (WHO Tuberculosis fact sheet 2008).  
3.2 The Indian Scenario
In India, 1.8 million Tuberculosis cases occur annually, accounting for one-fifth of the world’s 
new Tuberculosis cases and two-thirds of the cases in the South-East Asian region. This makes India 
the highest tuberculosis burden country in the world. It is estimated that two of every five Indians are 
infected  with  tuberculosis.  Of  them,  at  least  10% will  develop  Tuberculosis  disease  during  their 
lifetime.
Around  0.8  million  are  sputum positive  and  one  sputum positive  patient  can  infect  10-15 
persons in a year if left untreated. Tuberculosis is one of the leading causes of mortality in India, killing 
2  persons  every three  minute,  nearly  1,000 every day.  The  results  of  the  Drug Resistant  Surveys 
undertaken  in  Gujarat  and  Maharashtra  (2005-2006)  indicate  prevalence  of  MDR-TB  to  be  3% 
amongst new cases and 12 - 18% in re-treatment cases. In India, XDR TB has been reported by isolated 
studies with non-representative and highly selected clinical samples. The magnitude of the problem 
remains to be determined due to the absence of laboratories capable of conducting quality assured 
second line Drug Sensitivity Test (RNTCP Status Report 2008).
3.3 The Global Prevalence of Drug Resistance                                              The  2008 
WHO/IUATLD Global  Projects  on Anti-Tuberculosis  Resistance  Surveillance  report  includes  drug 
susceptibility  test  results  from  91,577  patients  from  93  settings  in  81  countries  and  2  Special 
Administrative Regions of China collected between 2002 and 2006. It is estimated that 489,139 cases 
emerged in 2006, and the global proportion of resistance among all cases is 4.8%. China, India and the 
Russian Federation are estimated to carry the highest number of MDR cases. China and India carry 
approximately 50% of the global burden and the Russian Federation a further 7%. 
Countries of the former Soviet Union are facing a serious and widespread epidemic, that almost 
half of all TB cases are resistant to at least one drug and every fifth case of TB will have MDR-TB. 
MDR-TB cases in this region have more extensive resistance patterns including some of the highest 
proportions of XDR-TB.
China ranked second, but has the highest burden of cases in the world.  It is estimated that over 
1 in 10 cases of MDR TB that emerged in 2006 globally occurred in patients in China without a history 
of prior anti-TB treatment (Anti-tuberculosis drug resistance in the world, WHO Fourth Global Report  
2008).
Compared with survey in 1997 at Poland, the 2000 survey showed no statistical difference in 
the rate of acquired resistance: 17.0% in 1997 and 16.6% in 2000. However, the MDR rate grew from 
7.0% to 8.5% (22% increase) and 50% increase in patients excreting  M.tuberculosis resistant to four 
drugs (1.4% in 1997 vs. 2.1% in 2000) (Augustynowicz-Kopec  et al 2000).
From January 1991 to December 2000, a total of 291 HIV-negative patients treated at Muniz 
Hospital were affected by MDR-TB. Of these, 212 (72.9%) were acquired MDR-TB cases (Domingo 
Palmero et al, 2003).
Of the countries that reported data on drug resistance stratified by HIV status in the WHO, 
Fourth Global Report 2008, any resistance and MDR were significantly associated with HIV.
 3.4 The Prevalence of Drug Resistance in India
Data from nine sites in  India  show that drug resistance among new cases is  relatively low 
however,  new data from Gujarat  indicate that  MDR is present  in 17.2% among retreatment cases, 
which is higher than what was previously anticipated and it is estimated that 110,132 MDR-TB cases 
emerged  in  India  in  2006,  representing  over  20%  of  the  global  burden (Anti-tuberculosis  drug 
resistance in the world, WHO Fourth Global Report 2008).
 A study conducted by the Institute of Thoracic Medicine, Chennai in four District Tuberculosis 
Centres of Tamil Nadu, showed that acquired resistance was 
63 %, of which 23.5 % was resistance to a single drug and 39.5 % to more than one drug. MDR-TB 
was reported in 20.3 % (Paramasivan CN, 1998).
Acquired resistance to Isoniazid was 61.76%, to Streptomycin was 51.52%, to Rifampicin was 
70.59% and to Ethambutol was 39.39%. Proportion of MDR- TB was 3.3% in new cases and 38.2% in 
old cases (Mathur et al 2000). 
Of the patients with history of previous treatment, isolates from 50% were fully susceptible. 
Resistance to Isoniazid, alone or with other drugs was seen in 50% cases, Rifampicin resistance was 
observed in 25%, all of whom were also resistant to Isoniazid (Paramasivan CN et al 2000).
At Indore, Madhya Pradesh resistance for Isoniazid, Streptomycin and Pyrazinamide was found 
to  be high (54.2%, 41.5% and 50% respectively)  followed by resistance to  Rifampicin (25%) and 
Ethambutol (22%). Only 12% of the isolates were sensitive to all  the anti-tuberculous drugs while 
resistance to two, three, and four or more drugs was in the range of 20-25%. MDR TB was 8.1% 
(Hemvani et al 2001). 
In previously treated cases, resistance to any drug was observed in 81.2%, and any resistance to 
Isoniazid, Rifampicin and both in 81%, 69% and 69%, respectively in North Arcot  (Tamilnadu). All 
previously treated patients were resistant to Isoniazid and Rifampicin (100%) in Raichur (Karnataka) 
(Paramasivan CN et al 2002). 
Shah et al 2002 studied previously treated pulmonary Tuberculosis patients and reported that 
resistance  to  Isoniazid  and  Isoniazid  plus  Rifampicin  was  12.86  and  
15.77 % respectively. 
Among the isolates from cases with previous history of treatment of varying duration, resistance 
to Rifampicin was 28.2% and to Isoniazid was 39.7%. 24.3% of these drug resistant isolates were 
multidrug resistant (Malhotra et al 2002). 
In a  study conducted by  Sophia Vijay et  al  2002 in  Bangalore,  the multidrug resistance in 
previously  treated  cases  was  found  to  be  12.8  %  and  ranged  from  8.4  to  
17.2 %. 
A retrospective study of drug resistance among treatment failure Tuberculosis cases observed a 
resistance of 42.5%. A high degree (14 %) of MDR-TB was observed. These patients claimed to have 
antituberculous therapy without improvement; however, 57.5% isolates were sensitive to all four first-
line drugs that were tested (Dam et al 2005).
3.5 Potential Causes for Drug Resistance
Drug resistant tuberculosis is a man made problem. Various factors have been implicated in the 
causation of MDR-TB .They are
3.5.1. Genetic Factors
There is some evidence to postulate host genetic predisposition as the basis for the development 
of MDR-TB, though it has not been conclusive (Weyer K Kleeberg 1992; Carpenter et al, 1983). In a 
study from India  (Sharma et al 2003), patients with HLA-DRB1*13 and -DRB1*14 were found to 
have two-fold increased risk of developing MDR-TB.  Park et  al 2002,  found that susceptibility to 
MDR-TB  in  Korean  patients  was  strongly  associated  with  HLA361  DRB1*08032-DQB1*0601 
heliotypes. 
3.5.2. Factors Related To Previous Anti Tuberculous Treatment
Incomplete and inadequate treatment: 
The most powerful predictor of the presence of drug resistant tuberculosis is a history of prior 
treatment  of  Tuberculosis.  Tuberculous  patients  in  India  get  treated with DOTS regimen not  only 
through RNTCP, but also receive treatment from private medical practitioners. Irregular, incomplete, 
inadequate treatment is the commonest means of acquiring drug resistant organisms  (Borgdorff et al  
2002, Sharma & Mohan 2006, Vasanthakumari et al 1997). 
Mahmoudi and Iseman 1993, observed that errors in management decisions like addition of a 
single  drug  to  a  failing  regimen,  failure  to  identify  preexisting  drug  resistance,  initiation  of  an 
inadequate  primary regimen,  inappropriate  Isoniazid preventive therapy and failure  to  identify and 
address noncompliance led to drug resistance.
A common error in prescription practice is the “addition syndrome”. If another drug is added 
to  the  existing  regimen  when  the  patient  appears  to  deteriorate  clinically  and  if  resistance  had 
developed to the drugs in use, adding another drug effectively amounts to monotherapy with the drug. 
Prescription  of  antituberculous  drugs  by  unqualified  persons  or  alternative  medicine 
practitioners in bizarre regimens for inadequate periods is an important problem in our country. Free 
availability of antituberculous drugs over the counter may contribute to this (Sharma & Mohan 2004). 
Inadequate treatment compliance: 
 Poor compliance with treatment is an important factor in the development of acquired drug 
resistance. In a study conducted in South India it was observed that only 43% of the patients receiving 
short-course treatment completed 80% or more of their treatment  (Datta et al 1993). Johnson et al 
2003, found a  high  incidence  of  drug resistance  in  previous  treatment  defaulters  than  in  the  new 
incident cases.
The studies on the association of demographic characteristics of patients to compliance of anti-
tuberculosis therapy have given inconsistent results (Sumartoyo et al 1993). 
An  Indian  study  revealed  that  the  socio-demographic  factors  like  age,  sex,  education, 
occupation and socio-economic status were not associated significantly with adherence (Pandit et al  
2006).
 Ashry Gad et al 1997 in their study portrayed the same fact that the factors like age, sex, work 
and education had no association with adherence of treatment. However default was significantly more 
among male patients, alcoholics and smokers in several other Indian studies. (Jaggarajamma et al  
2007; Pauline Joseph et al 2006). The studies by Sophia Vijay et al 2003 and Santha et al 2002 also 
suggest that males had twice the risk of treatment default than females.  Better treatment compliance 
among  women  than  men  have  been  reported  by  Ngamvithayapong-Yanai  et  al  1998  and 
Balasubramanian et al 2004. 
Pronab  Chatterjee  et  al  2003, observed  that  majority  of  patients  on  DOTS  discontinued 
treatment because of toxicity of drugs or due to feeling better during treatment.  Reasons for default 
from treatment like drug related problems, relief from symptoms, work related problems, treatment 
from other private or public health facility, domestic problems, stigma, too ill to attend, old age, other 
illnesses,  migration, inconvenient DOT and dissatisfaction with treatment centre and DOT provider 
were observed in studies of Sudha Ganapathy et al 1994, Jaggarajamma et al 2007 and Sophia Vijay 
et al 2003. 
Various studies revealed that the compliance of DOTS was significantly high among those who 
have good knowledge about various aspects of disease (Barnhoorn et al 1992; O’Boyle et al 2002; 
Thomas C, 2002).The adequate knowledge about disease was found to be the protective factor from 
defaulting therapy in Ethiopia (Tekle et al 2002). Increased probability of becoming infected with TB 
and developing active TB are associated with malnutrition, overcrowding, poor air circulation and poor 
sanitation- all factors associated with poverty (Kamolratanakul et al 1999). Studies from a number of 
developing countries reveal that the poor have much less access to DOTS programme than the non 
poor. A series of studies in India by Pathania et al 1997 have strongly correlated income with TB. 
Singh et al 2002, Balasubramanian et al 2000  and  Kemp et al 2001 observed that people living in 
poverty experience conditions that are more conducive to TB, have little access to health care, which 
delays  diagnosis,  and if  they get  treatment  it  is  more likely to  be inconsistent  leading on to  drug 
resistance. DOTS has the potential to reduce the economic and social burden of TB for patients and 
their households, however few studies have explicitly examined this question.
Bronchoalveolar  macrophages  among  smokers  contain  high  levels  of  iron,  promoting  the 
growth of M.tuberculosis. Iron loading causes reductions in TNF- α and nitric acid, which play a role in 
containing the intracellular growth of M.tuberculosis (Boelaert et al 2003). Studies by Joanna d’Arc et  
al  2008,  Thomas  et  al  2005  and Kolappan  et  al  2002 support  the  observation  that  smokers  are 
significantly  more  likely  to  relapse  than  nonsmokers.  Similarly  Santha  et  al  2000, observed  an 
association  between  smoking  and  treatment  failure  and  Chandrasekaran  et  al  2005, showed  that 
smoking was a risk factor to default from treatment.
3.5.3 Lack of Laboratory Diagnostic Facilities
The importance of timely detection of drug resistance in the optimal management of patients 
with tuberculosis has not been fully recognized for many years. Good, reliable laboratory support is 
seldom available in developing countries. Unfortunately, these are the areas where MDR-TB is a major 
health hazard. When facilities for culture and sensitivity testing are not available, therapeutic decisions 
are most often made by algorithms or inferences from previous treatment. Guidelines such as those 
published by the WHO are often resorted to choose the treatment regimen (Crofton et al 1997).
For patients categorized as treatment failure the WHO re-treatment regimen consists of three 
drugs  (Isoniazid,  Rifampicin,  and  Ethambutol)  for  a  period  of  eight  months,  supplemented  by 
Pyrazinamide  during  the  first  three  months  and  Streptomycin  during  the  first  two  months.  If 
mycobacterial culture and in vitro sensitivity testing are not routinely performed, it is not possible to 
establish  whether  these  patients  are  excreting  multidrug  resistant  bacilli  or  not.  If  this  WHO re-
treatment  regimen  is  administered  to  treatment  failure  patients  who actually  have  MDR-TB,  it  is 
evident  that  during  the  last  five  months  the  patient  will  be  receiving  Isoniazid,  Rifampicin  and 
Ethambutol only and this would amount to “monotherapy” with Ethambutol. Thus, “programmatic 
approach” to the management of “treatment failure” patients may fail in some settings.
Coninx R et al 1999 assessed the programme of tuberculosis control using first line therapy and 
DOTS in a prison setting in Baku, Azerbaijan. Resistance to two or more drugs, a positive sputum 
result  at  the  end  of  initial  treatment,  cavitary  disease,  and  poor  compliance  were  independently 
associated with  treatment  failure.  The author  concluded first-line therapy may not  be sufficient  in 
settings with a high degree of resistance to antibiotics. 
Espinal  et al 2000 made similar observations in another study with results of treatment with 
first line drugs for patients enrolled in the WHO and the IUATLD’s global project on drug resistance 
surveillance.  Patients  with  Tuberculosis  in  the  Dominican  Republic,  Hong  Kong  Special 
Administrative  Region (People’s  Republic  of  China),  Italy,  Ivanovoblast  (Russian  Federation),  the 
Republic of Korea, and Peru were studied in this retrospective cohort study. The data suggested that 
standard short course chemotherapy, based on first line drugs, is an inadequate treatment for some 
patients  with  drug  resistant  Tuberculosis.  Although  the  DOTS  strategy  is  the  basis  of  good 
Tuberculosis control, the strategy should be modified in some settings to identify drug resistant cases 
sooner, and to make use of second line drugs in appropriate treatment regimens. 
3.5.4. Other Co-Morbid Conditions
While not the documented greatest risk for MDR-TB, co infection with HIV and Diabetes deserve 
special addressing.
 HIV-TB: A Bidirectional Interaction:
HIV-infected persons are at markedly increased risk for progressive disease following primary 
tuberculous  infection (Liberato  et  al  2004). HIV  infection  also  increases  the  risk  of  subsequent 
episodes of Tuberculosis from exogenous reinfection (Sonnenberg et al 2001, Small et al 1993). The 
estimated annual risk of reactivation among those co-infected with HIV and TB is about 5 to 8 % with 
a cumulative lifetime risk of 30 % or more compared to HIV-negative adult patients  (Narain et al  
1992). 
In early 1990s, several institutional outbreaks of MDR-TB among HIV-infected patients drew 
attention to the problem (CDC Wkly Rep 1991; 1993; Fischl et al 1992). MDR-TB has been shown to 
be almost twice as common in tuberculosis patients living with HIV compared to TB patients without 
HIV. However current evidence suggests that HIV infection per se does not appear to be a predisposing 
factor for the development of MDR-TB.  The prevalent hypothesis is that HIV infection favours the 
transmission of multidrug resistant strains of M.tuberculosis.
Several factors such as
 (i) Increased susceptibility to Tuberculosis 
(ii)  Increased  opportunity  to  acquire  Tuberculosis  due  to  overcrowding,  exposure  to  patients  with 
MDR-TB due to increased hospital visits
(iii) Malabsorption of antituberculosis drugs resulting in suboptimal therapeutic blood levels in spite of 
strict adherence to treatment regimen
(iv) drug interactions between antiretrovirals and antimycobacterial agents,  potentially increase the 
chances of MDR-TB in persons with HIV/AIDS (Anti-tuberculosis drug resistance in the world, WHO 
Fourth Global Report 2008). 
Gordin et al 1996, New York, revealed that HIV infected TB patients were significantly more 
likely to develop resistance to at least one drug (37 versus 19%) and MDR (19 versus 6%) than those 
without HIV infection.
Kalpana et al 2004 observed that the level of MDR-TB in HIV positive was twice as high as in 
negative patients.
Among HIV-positive patients  with a history of  previous  treatment,  resistance was found to 
Isoniazid  in  27%  and  to  Rifampicin  in  18.9%  while  MDR-TB  was  seen  in  13.5%  patients 
(Swaminathan S et al 2005).
Sarman Singh et al 2007 observed resistance to first-line drugs in 50% of the isolates of HIV- 
tuberculosis co-infection and 33.33% of the isolates were also resistant to second-line drugs.
Diabetes Mellitus and TB-Converging Epidemics:
Diabetes affects 230 million persons worldwide, and this number is anticipated to reach 366 
million  by 2030,  at  which  time  80% of  those  affected  will  be  living  in  low and  middle  income 
countries, where active tuberculosis is widespread (Ruder et al 2007). Eight of the 10 countries with the 
highest incidence of DM worldwide (Wild et al 2004) are also classified as high-burden countries for 
TB by the World Heath Organization  (WHO report  2007). The consequences of these converging 
epidemics are likely to be substantial.
Diabetes  mellitus  predisposes  to  reactivation  of  tuberculosis  infection.  The  relative  risk  of 
developing  tuberculosis  is  up  to  five  times  higher  in  diabetics  (Kim et  al  1995).  The  reason  for 
increased susceptibility of diabetics to TB may be due to  
(i) Alveolar  macrophages  which  are  essential  to  eliminate  mycobacterial  infection  are  less 
activated in TB patients complicated with DM which may contribute to increased susceptibility (Wang 
et al 1999). 
(ii) In a study of TB patients with DM a higher depression of cellular immunity was evidenced 
by fewer T lymphocytes and their decreased capacity for blast-cell transformation than those with TB 
alone (Karachunskii et al 1997). 
(iii) Interferon gamma production by CD4+ T-cell was reduced in patients with TB but those 
with poor diabetic control produced significantly less IFN-gamma than did patients with good diabetic 
control (Tsukaguchi et al 2002). 
(iv) Changes in pulmonary vasculature and alveolar oxygen pressure may also be contributory 
(Kameda et al 1986).
 Studies indicate that patients with TB who have DM present a higher bacillary load in sputum, 
delayed mycobacterial  clearance  and higher  rates  of  multidrug resistant  infection.This  implies  that 
patients with TB who have DM may be more seriously ill and may pose higher risk for spread of drug-
resistant mycobacteria in the community. 
3.6 Non Tuberculous Mycobacteria:
As routine drug sensitivity testing is not performed under the National control programmes, the 
non-responsive cases are usually labeled as MDR. Though development of drug resistance is a reason, 
the  other  equally  important  fact  not  given  due  importance  is  the  occurrence  of  Non  Tuberculous 
Mycobacteria which has intrinsic resistance for the standard anti-tuberculous drugs.  
NTM, also known as atypical mycobacteria, are saprophytes naturally distributed in soil, water 
and dust. Their pathogenic potential has been recognized since the beginning of last century (Duvall et  
al 1908). These organisms have been reported to cause a variety of infections, more so in immuno 
compromised  individuals.  The  incidence  of  tuberculosis  has  reduced  in  developed  countries  but 
infections due to NTM are on the rise (Ferreira et al 2002), while in developing countries like India, 
tuberculosis is still a major health problem. Respiratory infections due to NTM are often associated 
with  various  conditions  such  as  chronic  obstructive  pulmonary  disease,  cystic  fibrosis  of  lung, 
bronchiectasis, emphysema of lung, previously treated pulmonary tuberculosis and lung cancer. 
M.kansasi, M.scrofulaceum, M.fortuitum, M.avium complex, M.xenopi and M.simiae have been 
reported to cause pulmonary infections (Katoch 2004). Jesudason et al 2005 reported that M.chelonae 
and  M.fortuitum  accounted for 67% of NTM isolated from respiratory specimens. Since NTM are 
ubiquitous  in  nature  and a  possible  laboratory contaminant,  the  isolation  of  these  organisms  from 
specimens should meet the criteria laid by the American Thoracic Society to confirm their etiological 
significance such as, 
a) Repeated isolation of the same organism from a patient,
b) Associated positive clinical and radiological evidence and 
c) Histopathological confirmation. 
need  to  be  considered  while  reporting  NTM  from  clinical  specimens.  However,  certain  other 
parameters like 
a) Collection of appropriate specimens directly from the lesion such as biopsies and BAL,
b) Isolation from sterile body fluids such as blood, CSF, pleural fluids,
c) Presence of any predisposing factors / underlying diseases and
d) The immune status of the patient
helps in assessing the etiopathogenesis of NTM when isolated (Katoch 2004;Wallace  et al 1990). 
 Karak et  al 1996  from Kolkata,  have reported a  NTM prevalence of 17.4% from sputum 
specimens from patients with fibrocavitary pulmonary diseases, this was comparatively higher than the 
reports of the other workers. Chakrabarthi et al 1990 from Chandigarh documented NTM isolation rate 
of 7.4% from various clinical specimens and M.fortuitum was the commonest isolate. Paramasivan et  
al 1985 from Chennai has reported 8.6% of NTM from sputum specimens of patients in BCG trial area 
and  M.avium / intracellulare  was the species most frequently isolated in their study.  Das et al 1982 
reported  isolation  of  8.3% NTM from various  clinical  specimens  from Delhi  and  Kasauli.  These 
infections are under diagnosed in many laboratories due to lack of facilities and expertise. Regular 
documentation and reporting of these NTMs from clinical settings along with their sensitivity profiles 
is essential to be aware of the possible spectrum of diseases associated and preferred treatment options. 
 The rates of MDR-TB in previously treated cases vary from 6-60% in our country. This is  a 
matter of serious concern. Continuous monitoring of the trends of drug resistance is essential to assess 
the current interventions and their impact on the TB epidemic. Above all ensuring adherence to a full 
course of treatment is the key to cure TB patients and prevent the emergence of drug resistance.
Materials and 
Methods
4. MATERIALS AND METHODS
The present study was conducted at the Department of Thoracic Medicine, Tirunelveli Medical 
College,  Tirunelveli  for  a  period  of  one  year  from May  2007  to  April  2008  to  assess  the  drug 
susceptibility profile of Category II patients registered under RNTCP. 
4.1 Study group
4.1.1 Inclusion criteria
 The study population constituted
1. Smear positive patients, with history of previous anti tuberculous treatment for more than one 
month comprising cases of Failure, treatment after Default and Relapse started on the CAT-II 
regimen.
2. Patients  who  had  completed  or  defaulted  Category  II  treatment,  found  to  be  still  sputum 
positive and referred to Tuberculosis Research Centre, Chennai for Drug Susceptibility Testing. 
3. The above cases that had been previously treated under RNTCP were alone included. 
4.2 Exclusion criteria
1. Extra pulmonary cases of Category II and  
2. Cases who had been previously treated privately were not included for the study.
Socio  demographic  and  clinical  characteristics  such  as  smear  status,  type  of  case,  type  of 
disease, category, treatment details such as drug regularity, number of doses taken by the patients and 
reasons  for  default  were  obtained  from patient.  Information  on  patient’s  literacy,  occupation,  and 
personal habits like smoking, other diseases like diabetes and HIV were also obtained.
4.3 Study Samples
Early morning sputum specimens were collected in a sterile container from the study group who 
were smear positive by Ziehl Neelsen method. Surface decontamination was done by immersing the 
specimen container in Lysol solution before transferring to the laboratory. All the laboratory works 
were carried out as per standard laboratory procedures and Bio-safety norms in Class II Biosafety 
cabinet. 
4.4 Acid-Fast Staining (Ziehl-Neelsen Method)
Mycobacteria retain the primary stain even after decolorizing with acid-alcohol, hence termed 
as ‘acid fast’. A counterstain is employed to highlight the stained organisms for easier recognition. In 
Ziehl-Neelsen procedure, acid-fast organisms appear pink against a blue background.
4.4.1 Procedure
1. The slides were placed on a staining rack with the smeared side facing up. 
2. Entire slide was flooded with strong carbol-fuchsin, which had been filtered before use.
3. Each slide was heated slowly until steaming, without allowing it to boil or dry. The steaming 
was maintained for five minutes by using intermittent heat.
4. Each slide was rinsed individually in a gentle stream of running water until all free stain was 
washed away.
5. The  slides  were  then  flooded  with  the  decolorizing  solution  (20% sulphuric  acid)  for  2-3 
minutes and rinsed thoroughly in a gentle stream of water to drain off excess stain.
6. The slides were then flooded with methylene blue counterstain for 30 seconds. Then the slides 
were rinsed thoroughly with water and smear was allowed to air dry. 
7. The  slides  were  examined  under  100x objective  lens,  maintaining  known positive  slide  as 
positive control and known negative slide as negative control.
4.4.2 Grading of AFB Smears by Z-N Microscopy in RNTCP
The smears were graded according to the RNTCP guidelines in Table - 4.1.
Table - 4.1 Grading of AFB Smears
No. of acid-fast bacilli Fields Report
(AFB)
No AFB In 100 immersion fields Negative
1-9 AFB In 100 immersion fields Record exact figure
(1-9 AFB/ 100 fields)
10 to 99 AFB In 100 immersion fields 1+
1 to 10 AFB Per field (examine 50 fields) 2+
More than 10 AFB Per field (examine 20 fields) 3+
4.5 Culture of Sputum Specimens
The  majority  of  clinical  specimens  submitted  for  tuberculosis  culture  laboratory  are 
contaminated to varying degrees by more rapidly growing normal flora organisms. These would rapidly 
overgrow the entire surface of the medium and digest it before the tubercle bacilli start to grow. The 
specimens  must,  therefore,  be  subjected  to  a  proper  digestion  and decontamination  procedure  that 
liquefies the organic debris and eliminates the unwanted normal flora.
4.5.1 Processing of Sputum Specimens by Sodium Hydroxide (Modified Petroff’s Method)
1. To X ml of sputum, 2X ml of 4% Sodium Hydroxide (NaOH) was added and shaken with 
tightened cap and allowed to stand for 15 minutes at room temperature.
2. The specimen was centrifuged at 3000g for 15 minutes and the supernatant was poured off.
3. The sediment was resuspended in 20ml of sterile distilled water and centrifuged at 3000g for 15 
minutes.
4. The supernatant was discarded and the sediment was inoculated in two slopes of Lowenstein 
Jensen medium in McCartney bottles. 
4.5.2 Processing of Sputum Specimens Containing Cetyl Pyridinium Chloride (CPC) and 
Sodium Chloride (Nacl) 
When the sputum specimens could not be cultured on the same day, they were processed within 
a week by CPC method. 
1. To the specimen with equal amount of CPC/NaCl, 15-20ml of sterile distilled water was added 
to reduce the viscosity.
2. Cap was tightened to the container and mixed well by inversion and was centrifuged at 3000g 
for 15 minutes. The supernatant was discarded.
3. The sediment was resuspended in 20ml of sterile distilled water and was centrifuged at 3000g 
for 15 minutes.
4. The supernatant was decanted and the deposit was inoculated onto two LJ slopes. 
4.6 Culture Examination 
Tubercle bacilli do not grow in primary culture in less than one week and usually require two to 
four weeks to give visible growth from sputum specimens. Typical colonies of  M. tuberculosis are 
rough,  crumbly,  waxy,  non-pigmented  (buff  colored)  and  slow-growers  having  the  appearance  of 
breadcrumbs or cauliflower. 
4.6.1 Examination Schedule
All cultures were examined within 48-72 hours after inoculation to detect gross contaminants. 
Thereafter  cultures  are  examined weekly,  up to  8  weeks  on a  specified  day of  the  week.  During 
examination, slopes in which the surface has been completely contaminated or where the medium has 
been liquefied or discoloured were discarded.
4.6.2 Reading of Cultures, Recording and Reporting of Results
All the slopes were held at 45° under tungsten filament lamp to observe the colony morphology 
clearly.
• All slopes that have completed 8 weeks of incubation and showed no growth were reported as 
‘negative’. 
• All  positives,  Non Tuberculosis  Mycobacteria  or  contaminated  cultures  were  taken  for  further 
examination. 
• Final results recorded: Negative, Contaminated and if positive the degree of positivity.
4.6.3 Reporting Of Positive, Negative and Contamination Results
The culture results were reported as per Table - 4.2 and 4.3. 
• If the degree of positivity was different on the two slopes, the highest degree was recorded.
• If neither of two slopes showed 20 colonies individually but the total on both slope was more than 
20 colonies it was 1+.
• If sum of colony was less than 20 on both slopes the actual number of colonies, was recorded.
• If one slope was positive and the other was negative the culture was reported positive with degree 
of positivity recorded and the slope showing no growth was re-incubated.
• If one slope was contaminated final result depended on the final examination of the remaining 
slope.
• If one slope showed the presence of NTM and the other slope was negative the final result was 
Negative / NTM.
• If both the slopes produced NTM at different weeks, the first NTM result in the final result column 
with the degree of growth was taken.
• If both the slopes showed NTM at the same week it was proceeded as for M. tuberculosis (grading). 
4.7 Biochemical methods for identification of mycobacteria
Identification of Mycobacteria species requires a battery of biochemical tests. The following 
tests, when used along with the morphological characteristics, will enable a precise identification of 
more than 95% of the M.tuberculosis strains.
1. Susceptibility to p-nitrobenzoic acid (PNB)
2. Niacin production test
Table - 4.2 Reporting of Cultures
READING REPORT
No growth Negative
1-19 colonies Positive (number of colonies)
20-100 colonies Positive (1+)
>100 discrete colonies Positive (2+)
Confluent growth Positive (3+)
Contaminated Contaminated
Table - 4.3 Reporting of Positive Culture Results
SLOPE 1 SLOPE 2
3+ 2+/ 1+ / No growth 
/NTM
3+
2+ 1+ / No growth / NTM 2+
1+ <20 Colonies / No 
growth / NTM
1+
< 20 <20 1+ (if sum of both slope is ≥20)
< 20 < 20 Actual number (if sum of both slope is < 
20)
<20 * Actual colony count
<20 NTM Actual colony count
<20 No growth Actual colony count
* * Contamination
* No growth Negative
* NTM NTM
No growth No growth Negative
No growth NTM Neg/ NTM
NTM NTM NTM (colonies or 1+ or 2+ or 3+)
* Contamination
4.7.1 Susceptibility to p-nitrobenzoic acid (PNB) 
The species of M.tuberculosis complex are susceptible to PNB (500μg /ml), whereas the NTM 
are resistant to PNB.
1. The neat bacterial suspension were inoculated onto two slopes of LJ medium without drugs and 
one slope of LJ medium containing p-nitrobenzioc acid (PNB) at a concentration of 500mg/litre 
and incubated at 37°C. 
2. Results read after 28 days.
M.tuberculosis does not grow on PNB medium.  All other mycobacteria are resistant.
4.7.2 Niacin Production Test
Niacin plays a vital role in oxidation reduction reactions that occur during metabolic synthesis 
in  all  Mycobacteria.  It  functions  as  a  precursor  in  the  biosynthesis  of  co-enzymes.  Although  all 
mycobacteria  produce  Nicotinic  acid,  comparative  studies  have  shown  that,  M.tuberculosis 
accumulates the largest amount and detection of this accumulated Niacin is useful for the definitive 
diagnosis of this species.
Reagents:
• O-toluidine  1.5%.
• Cyanogen bromide solution, approx. 10%.
Procedure:
1. All the LJ slopes were checked for water of condensation in culture tube, when needed 1 ml of 
sterile distilled water was added.
2. The culture bottles were then autoclaved for15 minutes at 121° C.
3. The bottles were placed in upright position for 20 - 30 minutes to allow the fluid to drain to the 
bottom. 
4. 0.25 ml of autoclaved culture extract was pipetted out into a clean screw capped tubes.
5. Sequentially 0.25ml of O-toluidine and 0.25ml of cyanogen bromide was added and mixed 
well.
6. The tubes were closed and solution was observed for the formation of pink color (positive) 
within five minutes.
7. H37RV as positive control and MAC as negative control were also maintained.
4.8 Drug Susceptibility Testing 
The drug sensitivity testing for the positive cultures were carried out at Tuberculosis Research 
Centre (ICMR), Chetput, Chennai.
The inoculum was prepared by using a representative sweep of the entire surface of the growth 
on the slope. The absolute concentration method uses a standardized inoculum grown on drug-free 
media and media containing graded concentrations of the drugs to be tested. Resistance is expressed in 
terms of the lowest concentration of the drug that inhibits growth; i.e., minimal inhibitory concentration 
(MIC).
4.8.1 Procedure:
Sterile distilled water 0.2ml was added to sterile bijou bottle with 10-12 glass beads (3mm 
diameter). Using a 3 mm internal diameter 24 SWG wire loop, two thirds of a loopful of representative 
sample of the bacterial mass that approximately equaled to 4 mg moist weight was taken and delivered 
into the bijou bottle. Bottle was vortexed for 30 to 60 seconds at a speed which will just lift the beads 
from the bottle and produce uniform suspension. 0.8ml sterile distilled water was added and the bottle 
was shaken by hand and the suspension was left inside the cabinet for 15-20 minutes, for the coarser 
particles settle down. Using a 3mm external diameter 27 SWG nichrome wire loop one loopful of this 
suspension was  inoculated  in  two drug free  slope  (control)  and  on  drug containing  slope  of  each 
concentration of the drug(s) and also one slope containing p-nitro-benzoic acid (500μg/ml) for each 
strain tested. The various drug concentrations used for absolute concentration method of DST are listed 
in Table - 4.4.
4.8.2 Incubation and reading of the tests:
The inoculated slopes were incubated at 37 ° C and examined for growth after 28 days of incubation.
• The lowest concentration of the drug inhibiting growth was recorded (MIC). The MIC for the drugs 
is given in Table - 4.5. 
• In this method ‘growth’ is defined by the presence of 20 colonies or more.  The test strain was 
considered to be resistant to the particular drug if the culture was positive above the MIC of each 
drug. The results were recorded as in Table - 4.6. 
All the above procedures were done as per the following guidelines.
1. RNTCP Training Module for Medical Practitioners, Central TB Division Directorate General of 
Health Services, Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi, 2006.
2. Canetti,  G,  Fox  W,  Khomenko  A,  Mahler,  H.T.,  Menon,  N.K.,  Mitchison.D.A   Advances  in 
techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis 
control programmes. Bull WHO, 1969; 41, 21-43
3. National  Committee  for  Clinical  Laboratory  Standards.  Susceptibility  testing  of  Mycobacteria, 
Nocardiae  and  other  aerobic  Actinomycetes.  Approved  Standard.  Wayne,  PA:  NCCLS;  2003. 
Document No.M24-A.
Table - 4.4 Drug Concentrations (µg/ml)
S.NO. DRUG H37RV TEST STRAIN
1. STREPTOMYCIN 2,4,8,16,32,64 8,16,32,64
2. ISONIAZID 0.025,0.05,0.1,0.2,1,
5
0.2,1,5
3. RIFAMPICIN 4,8,16,32,64,128 32,64,128
4. ETHAMBUTOL 0.5,1,2,4,8 2,4,8
5. KANAMYCIN 2,4,8,16,32,64 8,16,32,64
6. ETHIONAMIDE 20,28.5,40,57,80,114 20,28.5,40,57,80,114
7. OFLOXACIN 0.5,1,2,4,8 2,4,8
Table - 4.5 Minimum Inhibitory Concentration
SL.NO DRUG MIC(conc. of drug)
1. Streptomycin 8
2. Isoniazid 5
3. Rifampicin 128
4. Ethambutol 8
5. Kanamycin 64
6. Ethionamide 114
7. Ofloxacin 8
Table - 4.6 Grading of Culture slopes
GRADING CULTURE GROWTH
3+ Confluent growth
2+ Innumerable colonies (>100 colonies)
1+ 20-100 colonies
1-19 Actual number of colonies
     Results
5. RESULTS
5.1 The Study Group
A total  of 108 Category II  tuberculosis  cases were included for this  study.  These included 
patients residing in Tirunelveli district who were registered as Category II (Default, Failure & Relapse) 
under  RNTCP  at  the  Department  of  Thoracic  Medicine,  Tirunelveli  Medical  College  Hospital, 
Tirunelveli  and patients  who had failed Category II  and referred to Tuberculosis  Research Centre, 
Chennai from Tirunelveli for further management. The period of study was one year from May 2007 to 
April 2008.
Table – 01 Types of patients selected in the study group.
Sl.No. CASES
NO.  OF 
PATIENTS
PERCENTAGE
1 FAILURE 21 19.5
      CATEGORY I 19 17.4
      CATEGORY III 2 1.9
2 DEFAULT 39 36.1
3 RELAPSE 27 25.0
4 CATEGORY II FAILURES 21 19.4
TOTAL 108 100%
5.2 Statistical Analysis
The collected data were edited for completeness, consistency and accuracy. They were analysed 
by the parameters like mean, median and percentages. The differences of above parameters were tested 
by the  parametric  tests  like  ‘Z’  and‘t’  and  non-parametric  test  like  χ2 test,  which  was  applicable 
wherever. The statistical package used for analysis and interpretation is SPSS (version-13) with the 
level of significance P=0.05.
Fig. 01. Types of Patients Selected in the Study Group (in Percentage).
5.3 Analysis of risk factors for retreatment
5.3.1 Age and Sex
The selected 108 study subjects were analysed based on age and sex. The results of the analysis 
are tabulated in Table - 02 and Fig. 02. 
Table - 02. Age and sex wise distribution of the study subjects.
Sl. No Age group Male Female Total
1 10-19 2 2 4
2 20-29 9 6 15
3 30-39 21 5 26
4 40-49 21 4 25
5 50-59 24 5 29
6 60-69 5 0 5
7 70-79 4 0 4
Total 86 22 108
Mean 44.4 37.1 42.9
S.D 13.3 12.3 13.1
‘t’ 2.44
Significance P<0.05
The  analysis  shows  that  the  mean  age  of  female  is  37.1±12.3  and  of  male  is  
44.4 ±13.3.
The numbers of male patients in each age group was proportionately higher than that of female 
patients except in the age group of 10-19 and 60-79. It was highest in the age group 30-59 years. 
Fig. 02. Age and Sex wise distribution of the study subjects.
The sex wise distribution of cases under study is tabulated in Table - 03 and Fig. 03. 
Table – 03 Sex wise distribution of cases under study.
Sl. No Study group
Male Female Total
No. % No. % No. %
Significance
1 Defaulters 30 34.9 9 40.9 39 36.2 p > 0.05
2 Category  I 
Failure 
16 18.6 5 22.7 21 19.4 p > 0.05
3 Relapse 23 26.7 4 18.2 27 25 p > 0.05
4 Category 
II Failure
17 19.8 4 18.2 21 19.4 p > 0.05
Total  86 100 22 100 108 100 
Among the 108 cases, 86 were male (79.6%) and 22 were female (20.4 %). Of the 39 defaulter 
cases included under the study 30 were male (76.9%) and 9 were female (23.1%). Among the 21 Cat I 
failure cases 16 were male (76.2%) and 5 were female (23.8%). Of the total 27 relapse cases, 23 were 
male (85.1%) and 4 were female (14.9%). Among the 21 Category II failures who were referred to 
Chennai, 17 were male (80.9%) and 4 were female (19.1%).
However in comparison to the total male and female cases included under the study, there was 
no significance observed in relation to sex and each of the four study groups.
 Fig. 03. Sex wise distribution of cases under study.

5.3.2 Residence
Patients who resided within the Tirunelveli Corporation limits were taken as urban population 
and the others as rural population. (Table - 04, Fig. 04) 
Table - 04. Residence wise distribution of the study group.
Sl. No Study group
Rural Urban Total
No. % No. % No. %
Significance
1 Defaulters 28 36.8 11 34.4 39 36.2 p > 0.05
2 Failure 11 14.5 10 31.3 21 19.4 p >0.05
3 Relapse 22 28.9 5 15.6 27 25 p >0.05
4 Cat  II 
failure
15 19.8 6 18.7 21 19.4 p > 0.05
Total 76 100 32 100 108 100
The defaulters  of  rural  and  urban residents  are  36.8% and 34.4% respectively.  The  failure 
subjects of category I in rural and urban area are 14.5% and 31.3% respectively. The relapse cases of 
rural and urban area are 28.9% and 15.6% respectively. The Category II failure cases of rural and urban 
area are 19.8% and 18.7% respectively. The percentages are not statistically significant from the above 
results
 
Fig. 04. Residence wise distribution of the study group. 
5.3.3 Income
The average yearly income as stated by the patients was analysed (Table - 05, Fig. 05). 
Table - 05. Income wise distribution of the study group.
Sl. No Study group
More than 
25000 as 
yearly 
ncome.
Less than 
25000 as 
yearly 
income
Total
No. % No. % No. %
Significance
1 Defaulters 5 23.8 34 39.1 39 36.2 p > 0.05
2 Failure 5 23.8 16 18.4 21 19.4 p > 0.05
3 Relapse 4 19.1 23 26.4 27 25.0 p > 0.05
4 Cat  II 
failures
7 33.3 14 16.1 21 19.4 p > 0.05
Total 21 100 87 100 108 100
Only 21 cases had stated that their yearly income was above Rs. 25,000 (19.4%). The remaining 
80.6 % of cases earned less than Rs. 25,000 only and were considered as living below the poverty line 
for analysis.  Though a significant  percentage of cases in each of the study group lived below the 
poverty line, an association was not observed.   
Fig. 05. Distribution of study subjects and their income.
 
5.3.4 Education
Persons were considered as
Uneducated - Illiterate (unable to write their name) 
Literate (able to read and write, but having concluded less than the high 
school level) 
Educated - Above the high school level.
Their relation to the study group was analysed (Table - 06, Fig. 06). Among the 108 cases, 26 cases 
were  considered  educated  as  they  had  a  minimum  high  school  level  of  education  (24%).   The 
remaining 82 cases were uneducated (76%). There was no significant difference among the educated 
and uneducated in each of the study group.
Table - 06. Education wise distribution of the study group.
Sl. No Study group
Educated Un-educated Total
No. % No. % No. %
Significance
1 Defaulters 7 26.9 32 39.0 39 36.2 p > 0.05
2 Failure 6 23.1 15 18.3 21 19.4 p > 0.05
3 Relapse 8 30.8 19 23.2 27 25.0 p > 0.05
4 Cat  II 
failures
5 19.2 16 19.5 21 19.4 p > 0.05
Total 26 100 82 100 108 100
Fig. 06. Distribution of study subjects and their Educational Status.

5.3.5 Smoking Habit
Patients who gave a history of habitual smoking during the previous treatment but had 
stopped  at  present  and  who  were  currently  smoking  were  considered  smokers  for  the 
purpose of the analysis (Table - 07, Fig. 07). In this study only male subjects had the habit of 
smoking, so the analysis is ear marked to male subjects. Out of the 86 male cases, 64 were smokers 
(74.4%) and 22 were non smokers (25.6%). 
Smoking  habits  among  Defaulters,  Failure  cases,  Relapse  cases  and  Cat  II  failures  were 
analysed. It was found that smoking was a significant risk factor among Relapse cases, Category I and 
Category II failures.
Table – 07. Smoking habit as a risk factor among the study group.
Sl. No Study group
Smokers Non smokers Total
No. % No. % No. %
Significance
1 Defaulters 14 21.9 16 72.7 30 34.9 p <0.05
2 Failure 15 23.4 1 4.5 16 18.6 p<0.01
3 Relapse 21 32.8 2 9.1 23 26.7 p<0.01
4 Cat  II 
failures
14 21.9 3 13.7 17 19.8 p < 0.05
Total 64 100 22 100 86 100
Fig. 07. Smoking habit as a risk factor among the study group.
5.3.6 Diabetes 
History of Diabetes mellitus in the study group was analysed (Table - 08, Fig. 08).
Table – 08. Diabetes as a risk factor among the study group.
Sl. 
No
Study 
group
Diabetics Non diabetics Total
No. % No. % No. %
Significance
1 Defaulters 8 26.7 31 39.8 39 36.2 p >0.05
2 Failure 4 13.3 17 21.8 21 19.4 p>0.05
3 Relapse 11 36.7 16 20.5 27 25.0 p>0.05
4 Cat  II 
failures
7 23.3 14 17.9 21 19.4 p > 0.05
Total 30 100 78 100 108 100
Of the 108 patients, 30 patients were on treatment for diabetes. 9 patients were newly detected 
as diabetics based on the fasting blood sugar level of more than 140 mg/dl and postprandial level more 
than 180 mg/dl. Those who were on prior oral hypoglycemic drugs had moderate glycemic control with 
average serum glucose levels between 200 mg/dl and 300 mg/dl. The duration of diabetes, at the time 
tuberculosis was diagnosed varied from 1 year to long-standing disease of 10 years (average 6.4 years).
In the study group 30 cases (27.7%) were diabetic. There were more number of non-diabetics in 
the entire study group except among Category II failures, where 14 cases (66.6%) were found to be 
diabetic. There was no significance observed in relation to diabetic status and each of the four study 
groups. 
Fig. 08. Diabetes as a risk factor among the study group.
5.3.7 Regularity of Treatment 
Treatment was considered as being on a regular basis if the medication was used as prescribed. 
Treatment was considered irregular  if  there was default  in the use of medication for five or more 
consecutive doses provided it did not reach 30 days a month. The regularity of treatment was assessed 
and analysed for the study subjects (Table - 09, Fig. 09). 
Table – 09. Regularity of treatment among the study group.
Sl.
No.
Study 
group
Regular Irregular Total
No. % No. % No. %
Significance
1. Defaulters 10 23.3 29 44.6 39 36.2 P < 0.01
2. Failure 10 23.3 11 16.9 21 19.4 P > 0.05
3. Relapse 19 44.2 08 12.3 27 25.0 P >0.05
4. Category 
II failure 
4 9.2 17 26.2 21 19.4 P < 0.05
Total 43 100 65 100 108 100
Only 40% of the total cases had taken a regular treatment previously and the remaining 60% 
admitted that they had not strictly adhered to the treatment schedule. The percentages of patients on 
irregular treatment are statistically significant among defaulters and Category II failure cases.
Fig. 09. Regularity of treatment among the study group.
5.4 Reasons for Defaulting from Treatment
The reasons for default are enumerated in Table - 10, Fig. 10. The drug related problems like 
nausea, vomiting, giddiness were the leading causes for default (38.5%). The relief from symptoms and 
work related reasons scored equal chance for 17.9% persons to default.  Migration to  other distant 
places was a reason for default in 5.2% of cases. Domestic problems, too ill to attend, other illnesses, 
inconvenient DOT and dissatisfaction with treatment centers and DOT providers were the other reasons 
given for defaulting from treatment. 
Table – 10. Percentage distribution of reasons for default.
Sl.No. Reasons Default
No. %
1 Drug related problems 15 38.5
2 Relief from symptoms  7 17.9
3 Work related 7 17.9
4 Migration 2 5.2
5 Other problems 8 20.5
Total 39 100
Fig. 10. Reasons for defaulting treatment among the study group.
5.5 Culture Results
The culture results of the 108 cases are posted in Table - 11. 
Table – 11.  Culture results of the cases under study.
*Non tuberculous mycobacteria
Of the 108 samples processed, 85 sputum samples (78.7%) had given a positive culture result 
for M.tuberculosis. 23 of the remaining samples (21.3%) had either given a negative culture or was 
contaminated or had grown a Non-tuberculous mycobacteria. 13.8% of the total samples processed 
were  culture  negative,  3.7%  were  contaminated  and  3.7%  had  a  growth  of  Non  tuberculous 
mycobacteria
Fig. 11. Culture results of the cases under study.
Sl.
No.
Criteria
Total
cases
Cultur
e 
Positive
Others
Negativ
e
Contam-
ination 
 NTM
*
Total
1 Defaulters 39 33 4 2 0 6
2. Failure 21 14 5 1 1 7
3. Relapse 27 19 5 1 2 8
4 Category II 
failure 
21
19 1 0 1 2
Total 108 85 15 4 4 23
5.5.1 Non Tuberculous Mycobacteria (NTM)
The Niacin negative cultures were identified as a growth of Non tuberculous mycobacteria. The 
4 NTM cases are tabulated in Table - 12.
 Table – 12. Non tuberculous mycobacteria among the study group.
Sl.No. Study group No. of cases Regularity of treatment
Total 
duration of 
treatment
1. Cat I failure 1 Regular 5 years
2. Relapse 1 Regular 6 months
1 Regular 6 months
3. Cat II failure 1 Regular 11 months
All  the  4  cases  had  taken  treatment  regularly  as  specified  by the  physician.  3  of  them had been 
registered under Category II during the study period and one of the case was referred as Cat II failure.
5.6 Drug Sensitivity Results
 Among the culture positive 85 cases, drug sensitivity pattern was classified and the results are 
posted in the Table - 13. 
Table – 13. Study group wise drug susceptibility pattern.
Sl.No. Study group
Sensitive 
cases
Resistant 
cases
No. % No. %
Total
1. Defaulters 21 42.0 12 34.3 33
2. Failure 9 18.0 5 14.3 14
3. Relapse 17 34.0 2 5.7 19
4. Cat. II. Failure 3 6.0 16 45.7 19
Total 50 100 35 100 85
Among the 85 culture  positive cases  50 were sensitive to the first  line drugs (58.8%). The 
remaining  35 were resistant  to  one or  more  drugs  (41.2%).  Among the sensitive cases  42% were 
defaulters,  18% were  failures,  34% were relapse and the remaining 6% were category II  failures. 
Among the drug resistant group 34.3%, 14.3%, 5.7% and 45.7% were defaulters, failure, relapse and 
category II failures respectively. 
Of the 33 defaulters  registered for treatment, 21 cases were sensitive to the first line drugs 
(63.6%) and 12 cases were resistant (36.4%). Among the 19 relapse cases, 17 were sensitive to the 
drugs (89.5%) and 2 cases were resistant (10.5%). Among the 14 Failure cases, 9 were sensitive to the 
drugs (64.3%) and 5 cases were resistant (35.7%). Among the 19 Category II failure cases, 3 cases 
were sensitive to the drugs (15.8%) and 16 cases were resistant (84.2 %).   
5.6.1 Drug Resistance
The overview of resistance to the first line anti-tuberculosis drugs among the culture positive 
cases is enumerated in the Table - 14. 
Table – 14.
Percentage distribution of drug resistance.
Particulars
Cases
N %
Total patients recruited in the 
survey 108 100
Total patients with DST 
results(n=108) 85 78.7
Total patients with susceptible 
isolates(n=85 henceforth) 50 58.8
Total patients with drug resistance 35 41.2
Any resistance to H 27 31.7
Any resistance to R 19 19
Any resistance to E 3 3.5
Any resistance to S 21 24.7
Total patients with mono-resistance 14 16.6 
Resistance to H only 6 7.1
Resistance to R only 1 1.2
Resistance to E only 1 1.2
Resistance to S only 6 7.1
Total patients with poly resistance 21 24.7
Resistance to any 1 drug 14 16.6 
Resistance to any 2 drugs 9 10.6
Resistance to any 3 drugs 10 11.8
Resistance to any 4 drugs 2 2.4
Total patients with MDR TB 18 21.2 
Among the total culture positive cases cumulative drug resistance was most commonly seen to Isoniazid 
(27 patients 31.7%) followed by Streptomycin (21 patients, 24.7%). Resistance to Rifampicin was seen 
in 19 patients (22.3%) and to Ethambutol in 3 patients (3.5%).
 Mono drug resistance was noted in 14 patients (16.6%). It was most commonly seen with 
Isoniazid and Streptomycin (6 patients each, 7.1%), followed by Rifampicin and Ethambutol (1 patient 
each, 1.2%). 
Poly-drug  resistance  was  observed  in  21  patients  (24.7%).  Resistance  to  any  two  drug 
combination was seen in 9 patients (10.6%) and to any three drugs in 10 patients (11.8%). Resistance to 
all four drugs was seen in 2 patients (2.4%).
The resistance pattern for each of the drugs and the combinations is given in Table -15 and 
Table 16 in detail. 
Table – 15.Percentage distribution of resistance for each drug.
No Resistant To
Number 
resistant
Percentage of 
all cases 
(n=85)
Percentage of 
resistant cases 
(n=35)
1. ONE DRUG
SM 6 7.1 17.1
INH 6 7.1 17.1
RMP 1 1.2 2.9
EMB 1 1.2 2.9
TOTAL 14 16.6 40
2. TWO DRUGS
INH+SM 3 3.5 8.6
INH+RMP 6 7.1 17.1
TOTAL 9 10.6 25.7
THREE DRUGS
3 SM+INH+RMP 10 11.8 28.6
TOTAL 10 11.8 28.6
4. ALL FOUR DRUGS
SM+INH+RMP+EMB 2 2.4 5.7
TOTAL 2 2.4 5.7
GRAND TOTAL 35 41.2 100.0
Table – 16.Cumulative resistance to one or more anti – tuberculous drugs.
Sl.No. Resistant to Number Resistant
Percentage 
among all 
cases(n=85)
Percentage 
among 
resistant 
cases(n=35)
1. SM 21 24.7 60.0
2. INH 27 31.7 77.1
3. RMP 19 22.3 54.2
4. EMB 3 3.5 8.5
5. SM+INH 15 17.6 42.9
6. INH+RMP 18 21.2 51.4
7. SM+INH+RMP 12 14.1 34.3
8. SM+INH+RMP+EMB 2 2.3 5.7
5.6.2 Multidrug Resistant Tuberculosis
The  Multi  drug  resistant  T.B  cases  among  the  study  group  are  tabulated  in  
Table  -  17.  Among  the  85  culture  positive  cases,  18  were  MDR  TB  cases  (21.2%).Multi-drug 
resistance was 6.1% among the defaulters, 14.3% among the Failures, 10.5 % among the Relapse cases 
and 63.2% among the Category II failure cases. Among the 18 MDR TB cases, 66.7% were Category II 
failure cases and the remaining cases were 11.1% in the other study groups. 
Table – 17. MDR - TB in the culture positive cases.
Sl.
No.
Study group
Culture 
positive 
cases
MDR. T.B
No. %
% of M.D.R. TB 
(n=18)
1 Defaulters 33 2 6.1 11.1
2 Failure 14 2 14.3 11.1
3 Relapse 19 2 10.5 11.1
4 Category II Failure 19 12 63.2 66.7
Total 85 18 21.2 100
5.6.3 Second Line Drug Sensitivity
Of the 18 MDR cases, 9 cases were sensitive to all the second line drugs tested. Of the 9 cases 
that were resistant to the drugs, resistance to Ethionamide was seen in 5 cases, to and Ofloxacin in 1 
case. The Kanamycin and Ethionamide combination was resistant in 2 cases and Ethionomide plus 
Ofloxacin resistance was seen in 1 case.  Kanamycin plus Ofloxacin resistance (XDR-TB) was not 
observed in the present study.
Fig.12. Drug sensitivity pattern among the study group.
5.7 
HIV, 
TB 
and 
Drug 
Resistance
Among the 108 cases included under the study group, 8 cases were identified as HIV reactive at 
the  Integrated  Counselling  and  Testing  centre,  Tirunelveli  medical  college  hospital.  All  the  HIV 
reactive cases were male belonging to the rural areas. Among the 8 cases, 3 were drivers, 3 were 
agricultural labourers and 2 were cooly workers.  The cases are enumerated in Table -18. 
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Table -18. Percentage distribution of defaulters, failures, relapses and Cat II 
Failures with HIV.
Sl.No.
Study 
group
Reactive Non reactive
No. % No. % Significance
1 Defaulters 4 50.0 35 35.0 P<0.05
2 Failures 0 0 21 21.0 -
3 Relapse 3 37.5 24 24.0 P>0.05
4 Cat  II 
Failures
1 12.5 20 20.0 P>0.05
Total 8 100 100 100
In comparison to the total number of cases to HIV reactivity in each of the study group, significance 
was observed between defaulters and HIV reactivity only and not in relapse cases and Category II 
failures. 
The Culture results of the HIV reactive cases are given in Table -19. 
Table -19. 
Culture results of the HIV reactive cases.
1* - CONTAMINATED CULTURE
R- RIFAMPICIN, S- STREPTOMYCIN, I-ISONIAZID
Among the 39 defaulters included under the study, 4 cases were HIV reactive (10.3%). There 
SL.
NO.
STUDY GROUP
TOTAL
CASES
HIV
REAC-
TIV E
% 0F 
HIV
REACT-
IVITY
CULTURE
RESULT
DRUG
SENSITIVIT
Y
POS NEG SEN RES
RESIS-
TANT 
TO
1. Defaulter 39 4 10.3 4 - 3 1 R*
2. Failure 21 0 - - - - - -
3. Relapse 27 3 11.1 2 1* 2 - -
4. Cat II failure 21 1 4.8 1 - - 1 S,H,R*
were no HIV reactive Cat I failure cases registered during the study period. Out of the 27 relapse cases, 
3 patients were HIV reactive (11.1%) and among the 21 Category II failure cases, 1 patient was HIV 
reactive (4.8%).
One of the cultures was contaminated and drug sensitivity for the remaining 7 cases showed that 
2 cases were drug resistant. One case was a defaulter and the other was a Category II failure. The HIV 
reactive Defaulter showed monoresistance to Rifampicin and the HIV reactive Category II failure case 
was resistant to Streptomycin, Isoniazid and Rifampicin.
5.8 Analysis of risk factors for Multidrug resistance
5.8.1 Influence of Regularity of Treatment on Drug Resistance
The regularity of treatment and the total courses of treatment they had undertaken prior to being 
registered under Category II or referred to Chennai were analysed ( Table -20). Cases that had taken 
more than two months of treatment in each course was alone included. The drug sensitivity pattern in 
relation to the treatment particulars is tabulated. Of the 85 culture positive cases, 52 persons had taken 
single course of treatment (61.2%) and 33 persons had taken more than a single course of treatment 
(38.8%).
 Among the 52 culture positive cases who had taken a single course of treatment 36 cases were 
sensitive to the drugs (69.2%) and 16 were resistant to the drugs (30.8%). 
Among the 33 culture positive cases who had taken more than a single course of treatment 14 
cases were sensitive to the drugs (42.4%) and 19 were resistant to the 
drugs (57.6 %).
Table -20. Courses of treatment and Drug sensitivity pattern.
SL.NO. COURSES OF 
TREATMENT
CULTURE POSITIVE CASES
SENSITIVE RESISTANT TOTAL
NO. % NO. % NO. %
1. ONE 36 69.2 16 30.8 52 100
2. MORE THAN 
ONE
14 42.4 19 57.6 33 100
TOTAL 50 58.8 35 41.2 85 100
 
The percentage of MDR cases among those who had taken treatment regularly and irregularly were 
analysed. (Table- 21)
Table -21. Regularity of treatment in Multi-drug resistant cases.
SL.NO.
COURSES OF 
TREATMENT
REGULAR IRREGULAR
NO. MDR % NO. MDR %
SIGNIFICANCE
1. ONE 9 2 22.2 7 2 28.6 P>0.05
2. MORE  THAN 
ONE
1 0 0 18 16 88.8 P<0.00
TOTAL 10 2 20 25 18 72.0 P<0.001
Among the persons who had completed the single course of treatment regularly,  multi-drug 
resistance was observed in 22% of the cases.  Among those who had irregular treatment,  29% had 
multi-drug resistance.
Among the persons who had taken more than single course of treatment regularly multi-drug 
resistance was not observed in the study group. Among those who had taken irregular treatment 89% 
developed multi-drug resistant tuberculosis which was statistically significant.
5.8.2 Diabetes and Drug Resistance
Table- 22. Diabetes and drug resistance pattern among the study group.
Sl. 
No.
Drug  sensitivity 
pattern
Diabetics Non-diabetics
n No. % n No. %
Significance
1. Sensitive 24 14 58.3 61 36 59.1 P>0.05
2. Resistant 24 10 41.6 61 25 40.9 P>0.05
3. MDR 10 5 50.0 25 13 52.0 P>0.05
Of the 85 culture positive cases, 24 cases were diabetic (28.2 %).Among them 10 cases were 
drug resistant (41.6 %) of which 5 were multi-drug resistant (50%)
61 cases were non-diabetics. (71.8 %) and among them 25 were drug resistant cases (40.9%) of 
which 13 cases were multi-drug resistant (52 %).No significance was observed. 
5.8.3 Sex and Drug resistance 
Of the 65 culture positive male cases, 27 cases were drug resistant (41.5%) and among the drug 
resistant cases 14 were multi-drug resistant (51.9%).  
Table- 23. Sex wise distribution of Drug resistant cases.
Sl. 
No.
Drug sensitivity 
pattern
Male Female
n No. % n No. %
Significance
1. Sensitive 65 38 58.5 20 12 60.0 P>0.05
2. Resistant 65 27 41.5 20 8 40.0 P>0.05
3. MDR 27 14 51.9 8 4 50.0 P>0.05
Of the  20 culture  positive  female,  8  cases  were  drug  resistant  (40%) and among the  drug 
resistant cases 4 were multi-drug resistant cases (50%). No significance was observed.
5.8.4 Age and Drug resitance
Table -24. Age wise distribution of Drug Resistant cases.
Sl. 
No.
Drug sensitivity 
pattern
age ≤ 45 age> 45
n No. % n No. %
Significance
1. Sensitive 52 33 63.5 33 17 51.5 P>0.05
2. Resistant 52 19 36.5 33 16 48.5 P>0.05
3. MDR 19 11 57.9 16 7 43.8 P>0.05
Of the 85 culture positive cases, 52 cases were aged less than 45 years (61.2 %). Among them 
19 cases were drug resistant (36.5 %) of which 11 were multi-drug resistant cases (57.9%). 
33 cases were aged above 45 years (38.8%) and among them 16 were drug resistant  cases 
(48.5%) of which 7 cases were multi-drug resistant (43.8 %). No significance was observed.
5.8.5 Residence and Drug resistance 
Table -25. Residence wise distribution of Drug Resistant cases.
Sl. 
No.
Drug 
sensitivity 
pattern
Rural Urban
n No. % n No. %
Significance
1. Sensitive 63 38 60.3 22 12 54.5 P>0.05
2. Resistant 63 25 39.7 22 10 45.5 P>0.05
3. MDR 25 12 48.0 10 6 60.0 P>0.05
Of the 85 culture positive cases, 63 cases resided in the rural areas. (74.1 %).Among them 25 
cases were drug resistant (39.7 %) of which 12 were multi-drug resistant (48 %). 
22 cases resided in  the urban areas (25.9%) and among them 10 were drug resistant cases 
(45.5%) of which 6 cases were multi-drug resistant (60 %). No significance was observed.
5.8.6 Smoking habit and Drug resistance
Of the 85 culture positive cases, 65 were male cases. Among them 48 cases were smokers (53.1 
%). Of them 21 were drug resistant cases (43.7%) among which 13 were multi-drug resistant (61.9%). 
Table -26. Smoking habit wise distribution of Drug Resistant cases.
Sl. 
No.
Drug sensitivity 
pattern
Smoker Non-smoker
n No. % n No. %
Significance
1. Sensitive 48 27 56.3 17 11 64.7 P>0.05
2. Resistant 48 21 43.7 17 6 35.3 P>0.05
3. MDR 21 13 61.9 6 1 16.7 P<0.05
 17 male were non-smokers (64.7%) and among them 6 were drug resistant cases (35.3%) of 
which 1 case was multi-drug resistant (16.7 %).  Smoking had a significant association in MDR-TB.
5.8.7 Education and Drug resistance
Table -27. Educational status wise distribution of Drug Resistant cases.
Sl.No. Drug sensitivity pattern
Educated Un-educated
n No. % n No. % Significance
1. Sensitive 20 12 60.0 65 38 58.5 P>0.05
2. Resistant 20 8 40.0 65 27 41.5 P>0.05
3. MDR 8 5 62.5 27 13 48.1 P>0.05
Of the 85 culture positive cases, 20 cases were educated (23.5). Of them 8 were drug resistant 
(40.0%) among which 5 were multi-drug resistant (62.5%). 
65 cases were uneducated (76.5%) and among them 27 were drug resistant cases (41.5%) of 
which 13 cases were multi-drug resistant (48.1 %). No significance was observed.
5.8.8 Income and Drug resistance
Table -28. Income wise distribution of Drug Resistant cases.
Sl. No.
Drug sensitivity 
pattern
More than 
25000 as yearly 
income
Less than 
25000 as yearly 
income
n No. % n No. %
Significance
1. Sensitive 17 9 52.9 68 41 60.3 P>0.05
2. Resistant 17 8 47.1 68 27 39.7 P>0.05
3. MDR 8 4 50.0 27 14 51.8 P>0.05
Of the 85 culture positive cases, 17 cases had an annual income of more than 25,000 rupees. 
(20.0  %).Among  them 8  cases  were  drug  resistant  (47.1%)  of  which  4  were  multi-drug  resistant 
(50.0%). 68 cases had an annual income of less than 25,000 rupees. (80.0 %) and among them 27 were 
drug resistant cases (39.7%) of which 14 cases were multi-drug resistant (51.8%). No significance was 
observed.
Fig. 13. Risk factors among multi drug resistant cases
Discussion         
6. DISCUSSION
A total of 108 Category II tuberculosis cases were included for this study. Since Tirunelveli 
Medical College Hospital is a tertiary care centre, most of the tuberculosis cases were referred from 
medical officers throughout the district for expert opinion before being started on Category II or being 
referred to Chennai. The study group comprised of cases who had failed Category I or Category III of 
RNTCP, defaulters and relapse cases who were currently registered for re-treatment under RNTCP-
Category II and cases who had failed Category II earlier. 
6.1 Age and Sex
The  analysis  showed  that  the  mean  age  of  registering  for  re-treatment  in  female  cases  is 
37.1±12.3 and in male cases is 44.4 ±13.3. This shows that women are registered for re-treatment in the 
younger age than the men. Both male and female cases had notified for retreatment at middle age than 
the extremes of age in the present study. Balasubramanian et al 2004 also observed that the probability 
of notification decreased significantly with advancing age among both the sexes.
The number of male cases in the study group was more in age group 30-59 years, in which a 
large proportion of men are likely to be employed. Employed men may be unable to take leave from 
work to attend the health care settings and would have discontinued prior treatment.  The same finding 
that men were less likely to have successful treatment outcome was observed in a study within SAARC 
Countries.  Better  treatment  compliance  among  women  than  men  have  been  reported  by 
Ngamvithayapong-Yanai et al 1998 and Balasubramanian et al 2004. For men, being the head of the 
family, loss of job and fear of social isolation were reported as major reasons for discontinuation of the 
treatment (Uplekar et al 2001). 
In this study, significantly more male than female cases had been registered for re-treatment. 
The notification of smear-positive retreatment cases was also significantly higher among men than 
women  in  a  study  by  Balasubramanian  et  al  2004 where  more  women  than  men  felt  inhibited 
discussing their illness with family (21% vs. 14%). Atre et al 2004 also found that women have less 
access to information about tuberculosis than men. In the Indian context difficulty in getting married, 
harassment by in-laws, dismissal from the work were reported as major barriers for women to get 
appropriate treatment (Uplekar et al 1996).
In the present study, men were slightly more likely to default than women but the difference 
was not statistically significant. In comparison to the total male and female cases included under the 
study, there was no significance observed in relation to sex and each of the four study groups. Thomas 
et al 2004 also did not find an association between genders and relapse. The studies by Jaggarajamma 
et al 2007 (24% vs. 8%), Balasubramanian et al 2004 (19% vs. 8%), Sophia Vijay et al 2003 (90% of 
the male defaulted) and Santha et al 2002 (22% vs. 8%) suggest that male defaulted more than female. 
Sophia Vijay et al 2002 analysed the retreatment outcome and found that gender was not significant for 
treatment failure but men defaulted more.
Because  of  the  incompliance  noted,  gender  issues  are  significant  for  development  of  drug 
resistance. But an association was not found in the present study. An European study by Faustini et al  
2006 observed more  MDR cases  among men.  Barroso  et  al  2003 and Pande  et  al  2005 did  not 
associate gender and MDR TB.  
6.2 Residence 
In the present study no association was observed between cases in urban and rural areas for 
inclusion under retreatment similar to the finding made by  Uplekar et  al 1998. There was also no 
significant difference in drug resistance among the rural and urban cases under study. But the study of 
Deepak Almeida et al 2003 highlights an alarmingly high percentage of MDR TB in an urban area 
(51%) than a rural center (2%). For epidemiological reasons, there may be less onward transmission of 
multidrug-resistant strains in rural areas with low population densities. Residential overcrowding is a 
major causative factor behind the spread of TB in urban areas like Mumbai. Such overcrowding is not 
observed in an urban set up at Tirunelveli.   
6.3 Income
Though a significant percentage of cases in each of the criteria lived below the poverty line, an 
association was not observed to relapse or to default or to fail from treatment in the present study. The 
association known for centuries between TB and poverty also applies to MDR-TB but we found no 
significant  association  between  MDR-TB  and  family  income.  Poor  absorption  of  the  anti-TB 
medications  through  the  gastrointestinal  tract  was  believed  to  be  the  pathophysiologic  event  that 
resulted in sub therapeutic serum drug levels. Although several mechanisms have been proposed to 
explain  the  low  serum levels  of  drugs  in  patients,  the  nutritional  status  of  the  patient  may be  a 
contributing factor. Poor nutritional status results in a decrease in the plasma drug concentration time 
curve and an increased renal clearance of unbound drug. In effect, low serum levels of anti-TB drugs 
result in patients being administered fewer anti-TB medications or, in some cases, even monotherapy. 
The latter regimen could then lead to acquired drug resistance as observed by Byrd RP 2002.
6.4 Education  
Though  the  educated  study  groups  were  in  less  numbers  for  retreatment,  there  was  no 
association observed in the present study. The results of  Singh et al 2002 showed that literates were 
better informed and more aware of the various aspects of tuberculosis as compared to the illiterates. 
Few authors worldwide had the concern of investigating the patient’s educational level as a risk 
factor  for  MDR-TB.  Al Jarad et  al  1994,  London and  Murray et  al  2000, South Africa found no 
association with MDR-TB. Two Brazilian studies by Natal et al 2000 and Barroso et al 2003 revealed 
an association between MDR-TB and lack of school education.
6.5 Smoking Habit
It was found that smoking was a significant risk factor among relapse cases (33% vs. 9%), 
Category I (23% vs. 5%) and Category II failures (22 % vs. 14%) in the present study. 
Studies by Joanna d’Arc et al 2008 (Odds ratio 2.5), Thomas et al 2005 (18.1% vs. 7.3%) and 
Kolappan et al 2003 (Odds ratio 2.5) support the observation that smokers are significantly more likely 
to relapse than nonsmokers. Santha et al 2000, observed an association between smoking and treatment 
failure (Odds ratio 8.4). A study by Subodh Katiyar et al 2008 observed that 47% of the smokers had 
failed Category II treatment.
Although the number of smokers were high among defaulters (22% vs. 30%) in the study group, 
the difference was not statistically significant in the present study.  Santha et al 2000 (23% vs. 13%) 
also found no association despite the high percentage of smokers. However Chandrasekaran et al 2005 
(14.6% vs. 5.9%) showed that smoking was a risk factor to default from treatment.
There was a significant association between smoking and multidrug resistant tuberculosis in the 
present  study (62% vs.  17%). Barroso  et  al  2003 (60  % vs.  40  %)  identified  that  smoking  was 
associated with MDR-TB in their analysis. Ruddy et al 2005 identified smoking as a risk factor for 
Isoniazid resistance. However  Pande et  al 2005, India observed that  smoking had no relation to 
infection with MDR organism.
6.6 Diabetes
There was no evidence for an increased risk of retreatment and MDR TB among people with 
diabetes in the present study. A systematic review of 13 observational studies on the relation between 
diabetes and tuberculosis by Christie et al 2008 found consistent evidence for an increased risk of TB 
among people with diabetes. Patel et al 1989 and Ezung et al 2002 reported that tuberculosis was found 
to be the most common complicating illness in patients with diabetes mellitus.
Mona Bashar et al 2001 in his study found out that diabetic patients were more than five times 
as likely to have infection with a multi drug resistant strain of tuberculosis. But drug resistance to first 
line anti-TB drugs was not found to be associated with diabetes mellitus in studies of Rupak Singla et  
al 2003(0%) and Barroso et al 2003(8% ).  In a study by Subhash et al 2003 CMC, Vellore on patients 
with diabetes and Tuberculosis, only 26% of the diabetic subjects with tuberculosis had MDR TB, 
which ruled out an association between both.
6.7 Regularity of Treatment 
The percentages of patients on irregular treatment were statistically significant among defaulters 
(45% vs. 23%) and Category II failure case (26% vs. 9%) in this study. There was no significance 
observed among relapse cases and irregular treatment.
Sophia Vijay et al 2003 (80%), Santha et al 2000(Odds ratio 3.9%) observed that higher default 
rates were associated with irregular treatment as in the present study. However  Thomas et al 2005 
found that the patients who were irregular on treatment were twice as likely to relapse as those who 
were regular (20 % vs. 9%).
There is virtually a consensus among researchers regarding the fact that the number of previous 
treatments is a risk factor for MDR TB and our study confirmed this association. Pande et al 2005 
observed the prevalence of MDR-TB in patients with past history of ATT at two centres in Delhi to be 
44.7% and  20% which  was  statistically  significant  in  their  study.  84.8% of  MDR TB  cases  had 
irregular and interrupted treatment as reported by Vasanthakumari et al 1997. Poor past compliance to 
treatment (Odds ratio 6.6) was associated with MDR TB in the study of Sharma et al 2003.
Analysis of the abandoned and irregular treatments showed a higher risk of developing MDR 
TB in studies of Espinal et al 2001 and Central TB Division report 2006. Davies et al 1998 in Bombay 
proved the incidence to be over 50% in those who had previous irregular treatment. Barroso et al 2003 
observed that number of previous treatments (Odds Ratio 4.58) and irregular treatments (Odds ratio 
5.14) were significant risk factors for MDR TB.  Faustini et al 2006 observed that previous treatment 
was the strongest determinant of MDR-TB in Europe. 
A  study  by  Costello  et  al  1980 found  that  41%  patients  with  previous  treatment  for  TB 
developed drug-resistant TB, and the percentage increased with increasing duration of the previous 
treatment. 
Previous  anti-tuberculosis  chemoprophylaxis  (Odds  ratio  4.8)  by  Vargas  et  al  2006 and 
previous  TB-treatments  by  Clendenes  et  al  2002 were  observed  as  significant  risk  factors  for 
developing MDR TB in HIV patients. 
6.8 Reasons for Defaulting from Treatment
Reasons for default  from treatment like drug related problems, relief  from symptoms, work 
related problems, treatment from other private or public health facility, domestic problems, stigma, too 
ill to attend, old age, other illnesses, inconvenient DOT and dissatisfaction with treatment centre and 
DOT provider as stated by the study group were also observed in studies of  Jaggarajamma et al 2007,  
Pronab Chatterjee et  al  2003 and  Sophia  Vijay  et  al  2003.  The  other  reasons  like  distance  from 
treatment centre, lack of motivation and difficulty in DOTS timing as observed in other studies were 
not  stated as reasons to  default  because the DOT provider was accessible to the patient any time. 
However studies of  Jaggarajamma et al 2006, Sophia Vijay et al 2003 and Sudha Ganapathy et al  
1994 have brought out migration as an important factor for treatment default, which was observed only 
in 5% of the defaulters in the present study.
6.9 Culture Results
Of the 108 samples  processed,  85 (78.7%) showed a positive growth for  M. tuberculosis. 
13.9% of the total samples processed were culture negative, 3.7% were contaminated and 3.7% had a 
growth of Non Tuberculous Mycobacteria.
A negative culture result with the specimen containing tubercle bacilli may be due to several 
reasons. In patients receiving treatment, the organisms may have lost their ability to grow on a culture 
media  and be practically  dead.  Patients  being  treated  with  a  Rifampicin  containing  regimen often 
become culture  negative  by about  the  third  week  of  treatment,  although  they  may be  still  smear 
positive, the bacilli are dead or nonviable. The sputum specimens exposed to heat, stored too long, 
dried out or contaminated also yield a negative culture. Excessive decontamination procedures before 
inoculation, over heating before centrifugation, inadequate culture media and deficient incubation also 
result  in  a  negative  culture.  Positive  smears  may  be  caused  by  non-  tuberculous  mycobacteria 
(Toman’s Tuberculosis p.44-45).
6.9.1 Non Tuberculous Mycobacteria
If only a few colonies of non-tuberculous mycobacteria (NTM – often pigmented, with smooth 
morphology or PNB positive) were grown, it was taken as culture negative. More than 20 colonies of 
only NTM in both slopes were present in 4 cases in the study group. The pathogenic role of NTM could 
not be established in this study, since repeat isolation was not possible. The isolation rate was 3.7%. 
The isolation rate of NTM from India has been reported ranging from 0.5 percent to 8.6 percent in 
several studies by Sivasankaril et al 2006, Paramasivan et al  1985 &1986, Hardas et al 1984 and 
Pathak et al 1973. The reports of Karak et al from Kolkotta, shows an NTM prevalence of 17.4% from 
sputum specimens, much higher than the above studies.
Although none of the patients were HIV positive, isolation of these NTM strains show that 
these strains are re-emerging as potential  pathogens.  Regular documentation and reporting of these 
NTMs from clinical settings along with their sensitivity profiles is essential to be aware of the possible 
spectrum of diseases associated and preferred treatment options. 
6.9.2 Drug Sensitivity
The study group patients claimed to have taken anti-tuberculosis therapy without improvement; 
however, 50 (58.8%) isolates were sensitive to all four first-line drugs (INH, RIF, SM and EMB) that 
were tested. Resistance observed in this study was 41.2%.
The percentage of sensitivity among defaulters, Category I failures,  relapse and Category II 
failures was 63.6%, 64.3%, 89.5% and 15.8% respectively, showing that significant proportion of the
cases were sensitive to the drugs. The percentage of resistance among defaulters, Category I failures, 
relapse and Category II failures was 36.4%, 35.7%, 10.5% and 84.2 % respectively.
Default  and failure  patients  had high drug resistance than the relapse cases.  Except for the 
Category II failures in whom a high degree of resistance and low level of sensitivity was observed, all 
the  other  categories  showed  a  significant  level  of  drug  sensitivity.  This  study shows  that  all  re-
treatment cases can be adequately treated with the category II regimen and referring the Category II 
failures for drug susceptibility testing and further management to referral centres may be adequate. The 
low success  rate  to  the  CAT-II  regimen  was  mainly due  to  the  high  default  during  treatment.  If 
treatment compliance can be ensured for all  patients  registered to CAT-II regimen we can have a 
successful treatment outcome. Pauline Joseph et al 2006 also observed the same findings in their study.
6.9.3 Drug Resistance
Among all the culture positive patients (n=85) resistance to one drug was noted in 14 patients 
(16.6%), to two drugs in 9 patients (10.6%), to three drugs in 10 patients (11.8 %) and to all four drugs 
in 2 patients (2.4%). The similar pattern of resistance was observed by Shah et al, 2002 and  Sophia 
Vijay et al 2002 except for all four drugs which was 15.21% in the former and 4% in the latter.
  Single drug resistance was most commonly seen with Isoniazid and Streptomycin (6 patients 
each, 7.1%), followed by Rifampicin and Ethambutol (1 patient each, 1.2%). 
The present study shows high degree of resistance to Streptomycin similar to study of Sophia 
Vijay et al 2002 which showed resistance to Streptomycin in 9.3%, followed by  Isoniazid in 8.4%, 
Rifampicin in 1.8% and Ethambutol in 0 cases. This is in contrast to study of Shah et al 2002, which 
showed less resistance to Streptomycin, where the pattern of resistance was Isoniazid in 7.5%, followed 
by Streptomycin in 1.4%, Rifampicin in 0.97% and Ethambutol in 0.4%. 
Resistance to Isoniazid plus Rifampicin alone was seen in 6 patients (7.1%) similar to study of 
Shah et al 2002 which showed 9.2 % but 4.9% by Sophia Vijay et al 2002.
Most  of  the Rifampicin resistant  cases  were also resistant  to  Isoniazid.  This  has  also been 
observed in studies of Trivedi et al 1988 and Shah et al 2002.
When  comparing  resistance  to  individual  drugs  among  the  total  drug-resistant  cases  (35 
patients, 41.2%), cumulative resistance to Isoniazid was highest (31.7%), followed by Streptomycin 
(24.7%), Rifampicin (22.3%) and Ethambutol (3.5%). Resistance to Isoniazid was also found to be 
high in several studies. It was 15% in Bombay (Chowgule et al 1998), 27.4% in Bangalore (Sophia 
Vijay et al 2002), 41% in Chennai (Deivanayagam et al 2002), 57.18% in Gujarat (Shah et al 2002), 
61.76% in Jodhpur (Mathur et al 2000) and 81% in North-Arcot (Paramasivan  et al 2002).
Since resistance to Streptomycin was high in the present study, it was the second commonest 
drug for which resistance was observed unlike the above studies except 23% shown by Sophia Vijay et  
al 2002. 
All  the  above  studies  had  Rifampicin  resistance  in  the  second  place.  Drug  resistance  to 
Rifampicin in the present study was 22.3% which is similar to that reported from Jaipur 28.2% by 
Malhotra et al 2002, New Delhi 33.7% by Jain et al 1992, Gujarat 37.3% by Trivedi et al 1988 and 
Gujarat  37.47% by Shah et  al  2002 though Bombay reports  a  very high  incidence  of  Rifampicin 
resistance of 66.8% (Chowgule et al 1998).
Ethambutol was the least resistant drug in all the studies as in the present study, although the 
percentage was very less (3.5%) compared to 6.6% in Bangalore (Sophia Vijay et al 2002), Bombay 
8.4% (Chowgule et al 1998), Indore 22% (Hemvani et al 2001), Chennai 28.7% (Deivanayagam et al  
2002), Gujarat 35.45% (Shah et al 2002) and Jodhpur 39.39% (Mathur et al 2000).
6.9.4 Multidrug Resistant Tuberculosis (MDR-TB)
A high  degree  (21.2  %)  of  MDR-TB  was  observed  among  the  study group.  This  was  in 
accordance to most of the studies in India. Proportion of MDR- TB in re-treatment cases varied from 
100% Raichur, Karnataka, 69% North-Arcot study,  (Paramasivan CN et al 2002),  Jodhpur 38.2% 
(Mathur et al 2000), Jaipur 24.3 % (Malhotra et al 2002), 20.3 % (Paramasivan, 1998), 17.2%-Gujarat 
(Anti-tuberculosis drug resistance in the world, WHO Fourth Global Report 2008), Gujarat  15.77 % 
(Shah et al 2002), Gujarat 14 % (Dam et al 2005), Bangalore 12.8% (Sophia Vijay et al, 2002), Indore 
8.1%. (Hemvani et al 2001).
There is  concern regarding the efficacy of  CAT-II  regimen for  re-treatment  of TB patients 
especially for ‘Failure’ cases, since a high proportion of them may be having MDR-TB. In the present 
study, the percentage of MDR-TB in defaulters, Relapse and Category I failures was 11.1 % each and it 
was higher (66.7%) among the Category II failure cases. This study like that of Santha et al 2005 and 
Pauline Joseph et al 2006  shows that the RNTCP policy in India of treating all retreatment cases with 
the WHO recommended re-treatment regimen may be adequate except for the MDR-TB patients. DST 
should be  done for  patients  who remain  sputum smear  positive  during the retreatment  period and 
appropriate regimens should be started as early as possible for better treatment outcome and to reduce 
transmission of drug resistant TB. 
6.9.5 Extensively Drug-Resistant Tuberculosis (XDR-TB) 
Of the 18 MDR cases, 9 cases were sensitive to all the second line drugs tested. XDR-TB cases 
were not seen in the present study. Of the 9 cases that were resistant to the drugs, the resistance to 
Ethionamide was seen in 8 cases explaining cross-resistance of Ethionamide with INH. However, the 
fact that all tested isolates were resistant to isoniazid but one was not resistant to ETH might suggest 
that the mutations leading to drug resistance are located in different regions of the genome. Kanamycin 
resistance was seen in 2 cases, both of which had resistance to Streptomycin also. There is no cross 
resistance between Ofloxacin and other antituberculosis drugs but Flouroquinolones are the widely 
prescribed antibiotics for all infections explaining the emergence of drug resistance. 
Rajesh Mondal et al 2007, reported 7.4 % of XDR TB cases, the first ever report from India. A 
limitation to accurate detection of XDR TB is because; the existing tests for resistance to second line 
drugs is  not  yet  standardized and are  less reproducible  than results  for  first  line drugs. Only then 
second-line treatment can be individualized, based on in-vitro drug resistance, or can be standardized.
6.10 HIV, TB and Drug Resistance
Diagnosis of TB in HIV infected patients is difficult because of absence of fever and symptoms, 
negative  sputum  smears,  atypical  chest  radiographs,  higher  prevalence  of  EPTB  especially  at 
inaccessible sites and resemblance to other opportunistic pulmonary infections (Sharma et al 2004). 
Since smear positive cases were alone included in the present study, only 8 cases were found to be HIV 
reactive. More defaulters had HIV reactivity than any other group in the present study. Connolly et al  
1999, South Africa reports that being diagnosed for HIV was significantly associated with default. But 
Epco Hasker et al 2008, Tashkent finds no apparent association with default.
A review of the published literature by Ormerod LP 2005 and Sharma et al 2004, suggests that, 
in  the  early  1990s,  several  institutional  outbreaks  of  MDR-TB among HIV-infected  patients  drew 
attention to the problem. In this study,  HIV and MDR co-infection was seen in only one case and 
Rifampicin  monoresistance  was  observed  in  a  case.  Since  the  HIV cases  were  not  in  significant 
numbers, an attribute could not be made out. Studies of Barroso et al 2003, Spellman et al 1998, Asch 
et  al  1996 have found that MDR-TB is  not  more common among people infected with HIV. But 
Swaminathan   et al 2005 in their study have observed MDR-TB in 13.5 % of the retreatment HIV 
cases.  Sharma  et  al  2003 and  Jasmin Johnson  et  al  2003 have  demonstrated  Rifampicin 
monoresistance in HIV patients. 
     Summary
7. SUMMARY
The present study aimed at  finding the Drug susceptibility profile among previously treated 
pulmonary tuberculosis cases, analyse the risk factors that had led to the retreatment of the cases and 
identify the risk factors of MDR-TB
108 cases of retreatment pulmonary tuberculosis were included for the study for whom the risk 
factors for inclusion under Category II as defaulters, treatment failures or relapse cases were analysed. 
Specimens were cultured at  Tirunelveli  medical  college.  For  the  positive  cultures,  drug sensitivity 
testing was done at  Tuberculosis  Research Centre  (ICMR), Chetput,  Chennai.  The risk factors  for 
acquiring MDR TB were analysed.         
 Females  were  registered  for  re-treatment  in  the  younger  age  (37.1±12.3)  than  males  (44.4 
±13.3) and middle aged persons were in high numbers in both the sexes. 
 Males were highest in the age group 30-59 years, where most of them were employed and 
discontinued prior treatment.
 More males ( 79.6%) were registered for retreatment than females (20.4%)  suggesting  that 
while men were better able to access TB treatment from a DOT facility, the need to earn a 
livelihood acts as a barrier to complete treatment for them. 
 Women, on the other hand, have greater difficulty reaching an appropriate facility, but those 
who do, usually complete treatment.
 Area of residence, family income, education, gender were not risk factors for retreatment or 
MDR TB.
 Smoking was a significant risk factor among Relapse and Failure cases. It was also a significant 
risk factor to acquire MDR TB. 
 Diabetes was not a risk factor to default or relapse or fail from treatment and was also not a risk 
factor to acquire MDR TB. 
 Irregular and interrupted treatment was a risk factor among Defaulters and Failures and it also 
consistently led to the development of MDR TB. 
 Drug related problems like nausea,  vomiting,  giddiness (38.5%) were the leading cause for 
default. 
 8 cases were HIV reactive in the total study group. HIV cases were more among defaulters.
 HIV reactive defaulter showed monoresistance to Rifampicin. HIV reactive Category II failure 
case was multidrug resistant. 
 Of the 108 samples processed, 78.7% showed a positive growth for M. tuberculosis, 13.9% 
were culture negative, 3.7% were contaminated and 3.7% had a growth of Non tuberculous 
mycobacteria. Since repeat isolation was not possible for the NTM, its pathogenic role could 
not be established in this study. The patients have been registered for retreatment unnecessarily. 
 Among the 85 culture positive cases, 50 (58.8%) were sensitive to the first line drugs and 35 
(41.2%) were resistant to one or more drugs. 
 Among the 50 sensitive cases 42% were defaulters, 18% were failures, 34% were relapse and 
6% were category II failures. 
 Among the 35 drug-resistant  cases 34.3% were defaulters,  14.3% were failures,  5.7% were 
relapse, and 45.7% were category II failures. 
 Of the 33 defaulters, 21 (63.6%) were sensitive and 12 (36.4%) were resistant. 
 Of the 14 failure cases, 9 (64.3%) were sensitive and 5 (35.7%) were resistant.  
 Of the 19 relapse cases, 17 (89.5%) were sensitive and 2 (10.5%) were resistant. 
 Of the 19 Category II failure cases, 3 (15.8%) were sensitive and 16 (84.2 %) were resistant.   
 Resistance to one drug was noted in 14 (16.6%), to two drugs in 9 (10.6%), to three drugs in 10 
(11.8 %) and to all four drugs in 2 (2.4%) cases. 
 Monodrug resistance was most commonly seen with Isoniazid and Streptomycin (6 patients 
each, 7.1%), followed by Rifampicin and Ethambutol (1 patient each, 1.2%).
 Among the 35 drug resistant cases, cumulative resistance was highest to Isoniazid (27 patients 
31.7%) followed by Streptomycin (21 patients, 24.7%), Rifampicin (19 patients, 22.3%) and 
Ethambutol (3 patients, 3.5%).  
 18 were MDR TB (21.2%) among the culture positive cases. Among the 18 MDR TB cases, 
66.7% were Category II failure cases and 11.1% in the each of the other study groups.
 No XDR TB cases were present.  The treatment of MDR-TB becomes difficult since Second 
Line Drugs must be used, which are less potent and not as well tolerated as first-line agents. 
Susceptibility  testing  of  M.tuberculosis  to  SLDs  is  difficult,  expensive,  and  not  well 
standardized.
Conclusion
8. CONCLUSION
 Age,  sex,  residence,  education,  income,  diabetes  were  not  risk  factors  for  retreatment 
tuberculosis and multidrug resistant tuberculosis.
 Smoking was a significant risk factor among relapse, failure and MDR cases. There is a need to 
devise effective strategies for counselling patients about the impact of smoking on their cure.
 Irregular and interrupted treatment was a risk factor among defaulters, failures and multidrug 
resistant cases. Ensuring adherence to a full course of treatment is the key to cure TB patients 
and prevent the emergence of drug resistance.
 Drug related problems like nausea, vomiting, giddiness were the leading cause to default from 
treatment. The innovative strategies in health education are the need of the hour.
 HIV reactivity was noted among defaulters in the present study and not among MDR cases.  
 As drug sensitivity  testing  is  not  routinely performed,  NTM cases  had  been  registered  for 
retreatment unnecessarily.
 Though registered for retreatment, most of the isolates were sensitive to all the first line drugs 
and hence can be successfully treated with a category II regimen if they are compliant enough.
 Drug resistance was more among prior treatment failure cases, necessitating the need for timely 
culture  and  sensitivity  testing  for  those  who  remain  sputum positive  during  the  course  of 
treatment to curb the spread of multidrug resistant strains.
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Annexure –I
(Media preparation)
ANNEXURE I
PREPARATION OF 4% NaOH :
Dissolve 4 gm of sodium hydroxide in 100 ml of distilled water. Sterilize by autoclaving. Kept 
at 37 °C until use.
PREPARATION OF 1%CPC-NaCl:
One gm of cetylpyridinium chloride and two gms of sodium chloride are dissolved in 100ml of 
sterile distilled water and distributed in 5 ml aliquots in sterile MacCartney bottles. The stock solution 
should be stored in dark coloured bottles at room temperature. 
PREPARATION OF LOWENSTEIN-JENSEN MEDIUM:
Preparation of Mineral salt solution with malachite green:
Dissolve 37.24 gms of Himedia Lowenstein- Jensen media base and 12 ml Glycerol in 600 ml 
distilled water. Sterilize by autoclaving.
Homogenised whole eggs:
Fresh country hen’s eggs, those are not more than seven days old, are cleaned by scrubbing 
thoroughly with a hand brush in water and soap. Let the eggs soak for 30 minutes in soap solution. 
Rinse eggs thoroughly in running water and soak them in 70% ethanol for 15 minutes. Crack the eggs 
into a sterile flask and beat them in a sterile blender. 
Preparation of complete medium:
The following ingredients are aseptically pooled in a large, sterile flask and mixed well:
Mineral salt solution with malachite green- 600ml
Homogenized eggs (25-30 eggs, depending on size) 1000ml
The complete egg medium is distributed in 6-8ml volumes in sterile MacCartney bottles and the 
caps tightly closed and inspissated without delay to prevent sedimentation of heavier ingredients.
Sterility check:
After inspissation, the whole batch of the media bottles should be incubated 37 deg C for 24 
hours as a check of sterility.  After 24 hours 5% of the slopes should be picked up randomly and 
continued incubation. In both the cases the contamination rate should not be more than 10 %.
Storage:
The LJ medium should be dated and stored with the batch number in the refrigerator and can be 
kept for up to 4 weeks if the caps are tightly closed to prevent drying out of the medium.
Medium Containing P-Nitrobenzoic Acid
Weigh out 0.5 gm PNB and dissolve in the minimum amount of dimethylformamide (~15ml). 
Add to 1 litre of L-J fluid, distribute and inspissate once for 50 minutes at 85 °C. Store at 4 °C.
Niacin test:
Reagents
1) O-toluidine - 1.5% (O-toluidine - 1.5 g and Ethanol -100ml)
Mix in an amber coloured bottle and store it in the dark, in a refrigerator, prepare fresh weekly.
2) Cyanogen bromide solution, approx. 10%.
Store at 4 ° C in the refrigerator.
Preparation of drug containing LJ media:
1. Isoniazid
Stock solution preparation:
Weigh out 200 mg of Isoniazid in 20ml of sterile distilled water (10,000 µg/ml). Dissolve and 
sterilize by membrane filtration. Keep filtered solution frozen up to one month.
Working solution preparation:
Sl.No. Stock Solution Distilled Water(Ml) Concentration(µg/ml)
1. 1 ml of 10,000 µg/ml 9 1000
2. 2 ml of 1000 µg/ml 18 100
3. 1 ml of 100 µg/ml 19 5
4. 2 ml of 5 µg/ml 8 1
Media preparation:
Sl.No. Stock Solution LJ Fluid(ml) Final Concentration(µg/ml)
1. 2.5 ml of 1 µg/ml 100 0.025
2. 5 ml of 1 µg/ml 100 0.05
3. 2 ml of 5 µg/ml 100 0.1
4. 1.2 ml of 100µg/ml 600 0.2
5. 6 ml of 100 µg/ml 600 1.0
6. 3 ml of 1000 µg/ml 600 5.0
2. Rifampicin
Stock solution preparation:
Weigh out 200 mg of Rifampicin in 20ml of dimethyl formamide (10,000 µg/ml).
Working solution preparation:
Sl.No. Stock Solution Distilled Water(ml) Concentration(µg/ml)
1. 4 ml of 10,000 µg/ml 16 2000
2. 2 ml of 2000 µg/ml 18 200
Media preparation:
Sl.No. Stock Solution LJ Fluid(ml) Final Concentration(µg/ml)
1. 7.68 ml of 10,000 µg/ml 600 128
2. 3.84 ml of 10,000 µg/ml 600 64
3. 9.6 ml of 2000 µg/ml 600 32
4. 8 ml of 200µg/ml 100 16
5. 4 ml of 200 µg/ml 100 8
6. 2 ml of 200 µg/ml 100 4
3. Ethambutol
Stock solution preparation:
Weigh out 270 mg of Ethambutol in 20ml of distilled water (10,000 µg/ml). Dissolve and sterlize by 
membrane filtration.
Working solution preparation:
Sl.No. Stock Solution Distilled Water(ml) Concentration(µg/ml)
1. 2 ml of 10,000 µg/ml 18 1000
2. 10 ml of 1000 µg/ml 10 500
3. 1 ml of 500 µg/ml 9 50
MEDIA PREPARATION:
Sl.No. Stock Solution LJ Fluid(ml) Final Concentration(µg/ml)
1. 1ml of 50 µg/ml 100 0.5
2. 2 ml of 50 µg/ml 100 1.0
3. 2.4 ml of 500 µg/ml 600 2.0
4. 4.8 ml of 500µg/ml 600 4.0
5. 4.8 ml of 1000 µg/ml 600 8.0
4. Streptomycin
Stock solution preparation:
Weigh out 250 mg of Streptomycin in 20ml of distilled water (10,000 µg/ml). Dissolve and 
sterilize by membrane filtration.
Working solution preparation:
Sl.No. Stock Solution Distilled Water(ml) Concentration(µg/ml)
1. 4 ml of 10,000 µg/ml 16 2000
2. 1 ml of 2000 µg/ml 19 100
Media preparation:
Sl.No. Stock Solution LJ Fluid(ml) Final Concentration(µg/ml)
1. 2ml of 100 µg/ml 100 2
2. 4 ml of 100 µg/ml 100 4
3. 2.4 ml of 2000 µg/ml 600 8
4. 4.8 ml of 2000µg/ml 600 16
5. 9.6 ml of 2000 µg/ml 600 32
6. 3.84 ml of 10,000 µg/ml 600 64
5. Kanamycin:
Stock solution preparation:
Weigh out 128 mg of Kanamycin in 10ml of distilled water (10,000 µg/ml). Dissolve and sterlize by 
membrane filtration.
Working solution preparation:
Sl.No. Stock Solution Distilled Water(ml) Concentration(µg/ml)
1. 4 ml of 10,000 µg/ml 6 4000
2. 2 ml of 10,000µg/ml 18 1000
3. 1 ml of 1000 µg/ml 19 50
Media preparation:
Sl.No. Stock Solution LJ Fluid(ml) Final Concentration(µg/ml)
1. 2ml of 50 µg/ml 50 2
2. 4 ml of 50 µg/ml 50 4
3. 2.4 ml of 1000 µg/ml 300 8
4. 4.8 ml of 1000µg/ml 300 16
5. 2.4 ml of 4000 µg/ml 300 32
6. 4.8 ml of 4000 µg/ml 300 64
6. Ethionamide:
Stock Solution Preparation:
Weigh out  200 mg of  Ethionamide  in  20ml  of  tri-ethylene  glycol.  Mix  well  and  incubate 
overnight for self sterilization (10,000 µg/ml). Do not sterlize by membrane filtration.
Working solution preparation:
Sl.No. Stock Solution Distilled Water(ml) Concentration(µg/ml)
1. 6 ml of 10,000 µg/ml 14 3000
2. 8.55 ml of 10,000µg/ml 11.45 4275
Media preparation:
Sl.No. Stock Solution LJ Fluid(ml) Final Concentration(µg/ml)
1. 2ml of 3000 µg/ml 300 20
2. 2 ml of 4275 µg/ml 300 28.5
3. 4 ml of 3000 µg/ml 300 40
4. 4 ml of 4275µg/ml 300 57
5. 8 ml of 3000 µg/ml 300 80
6. 8 ml of 4275 µg/ml 300 114
7. Ofloxacin:
Stock Solution Preparation:
Weigh out 100 mg of Ofloxacin in 10ml of sterile 0.1 N NaOH (10,000 µg/ml). 
Working solution preparation:
Sl.No. Stock Solution Distilled Water(ml) Concentration(µg/ml)
1. 2 ml of 10,000 µg/ml 18 1000
2. 1 ml of 1000µg/ml 19 50
Media preparation:
Sl.No. Stock Solution LJ Fluid(ml) Final Concentration(µg/ml)
1. 1ml of 50 µg/ml 100 0.5
2. 2 ml of 50 µg/ml 100 1.0
3. 1.2 ml of 1000 µg/ml 600 2.0
4. 2.4 ml of 1000 µg/ml 600 4.0
5. 4.8 ml of 1000 µg/ml 600 8.0
Annexure –II
                 (Proforma of the Data sheet)
ANNEXURE II
DATA SHEET FOR COLLECTION OF SOCIO DEMOGRAPHIC, CLINICAL AND 
LABORATORY DATA 
FOR  P.G. DISSERTATION WORK ON  
“EVALUATION OF THE DRUG SUSCEPTIBILITY PROFILE AMONG CATEGORY II 
PULMONARY TUBERCULOSIS PATIENTS (RELAPSE, FAILURE, DEFAULTER) AT 
TIRUNELVELI”
Name:                                                                                                    Age/Sex:
Address: Rural/ Urban
Occupation:                                                                                           Income: 
Education:
Smoking habit:
H/O PRESENT ILLNESS:
            COUGH: Duration
                 Dry/ productive
                 Purulent/ watery/mucoid
                 Haemoptysis
            FEVER:   Duration
                 Continuous/ Intermittent.
                 Evening rise of temperature.
            LOSS OF APPETITE: 
            LOSS OF WEIGHT: 
            WHEEZING:
CHEST PAIN: Site
                          Pricking/ compressing
                          Radiating
                          Associated with cough
            BREATHLESSNESS: mild / moderate / severe exertion 
TREATMENT HISTORY: 
[FOR PATIENTS STARTED ON TMT/ CATEGORY II FAILURES]
CATEGORY I/ II/ III
            CATEGORY II- RELAPSE / DEFAULTER / FAILURE.
            DOTS/ NON DOTS:
            Treatment started on:
            At which hospital:
                          Sputum results:
           Month Date DMC Lab No. Smear 
result
Weight
Pretreatment
End IP/Extended IP
2 months CP
End treatment
             Treatment outcome:
                                     Cured/ Completed/ Failure/ Defaulted/Transferred out/ Died 
             Patient follow up:
PAST HISTORY:
H/o previous Anti TB treatment:  YES / NO
If YES: 
        CATEGORY I/ II / III/ NOT KNOWN
How long back:
At which hospital: PRIVATE / GOVT
Sputum results: positive/ negative/not known.
Duration of treatment:
Regular/ irregular:
Defaulted: 
Reason for default:
Treatment outcome: Cured/ Completed/ Failure/ Transferred out/ Died
Further management:
Treatment history if available from previous records:
H/o Diabetes/ Bronchial asthma/Others
Treatment particulars:
FAMILY HISTORY:
Family members:
Any other family member taking tmt for Tuberculosis:
Are they suffering from any signs suggestive of TB?
INVESTIGATIONS:
BLOOD SUGAR- RANDOM
                             -FASTING 
     -POSTPRANDIAL   
HIV STATUS: [AS PER ICTC REPORTS]
SPUTUM PROCESSED ON: 
CULTURE READING: --------------------- WEEKS   * / + / ++ / +++
*       CONTAMINATION
+++ CONFLUENT GROWTH
++     INNUMERABLE DISCRETE COLONIES
+       20-100 COLONIES
NIACIN TEST: 
GROWTH IN PNB:
DRUG SENSITIVITY RESULT:                          SECOND LINE DRUG TESTING:
S / R – STREPTOMYCIN                                    S / R – KANAMYCIN                                     
S / R – ISONIAZID                                              S / R –ETHIONAMIDE
S / R – RIFAMPICIN                                           S / R – OFLOXACIN   
S / R – ETHAMBUTOL  
INFERENCE:
 
